60 results on '"S. D'orazio"'
Search Results
2. P261 OUT–OF–HOSPITAL CARDIAC ARREST (OHCA): TWO–YEAR OBSERVATIONAL STUDY
- Author
-
C Condello, N Gasparetto, L Cacciavillani, S Orazio, D Betta, V Menegon, M Bussola, M Ferramosca, P Zanatta, C Cernetti, and S Iliceto
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
Background Cardiac arrest is the third cause of death in Europe. It is a medical emergency characterized by high mortality and morbidity. Myocardial infarction is the leading cause of cardiac arrest. Data collection through national and international registries is essential to advance knowledge and improve diagnostic and therapeutic practices. Purpose: we assess the epidemiological impact of OHCA within a territory of approximately 300.000 inhabitants and follow patients’ intrahospital clinical pathway with the aim to identify possible predictors of survival and neurological outcome. Methods an electronic database is used to collect and share data across the Emergency Medical Services (EMS) and reference Cardiologists. Respectively, the EMS collects out–of–hospital patient data, whereas Cardiologists collect all information about intrahospital progress. Results during an observation period of two years, 100 patients with OHCA were enrolled. The majority were male and the average age was 65 years old. The first rhythm identified was shockable in 41% of the cases. Witnesses performed cardiopulmonary resuscitation and used automatic external defibrillator respectively in 57% and 10% of the cases. Only 34% of the victims obtained ROSC and were admitted into the cardiac intensive care unit and half of them died before discharge. Within this group, cardiac arrest was caused by myocardial infarction in 46% of the cases. Of these, culprit lesion was located in the left anterior descending artery in 46,2 % of the cases. It appears that a blood pH value below 7,04 – measured at the arrival in Emergency Department – is a poor prognostic predictor of ROSC, with a 79% sensitivity and 86% specificity (AUC 0,81, 95% CI 0,644 – 0,977). On the other hand, a plasma level of lactic acid expresses multiorgan damage secondary to cardiac arrest and therefore represents a predictor of survival and neurological outcomes, but not ROSC. Conclusion during the two years of observation, the incidence of OHCA turned out to be slightly lower compared to the data available in the literature. Mortality remains extremely high: only 12% of the population survives, of which 16% with poor neurological outcome. Blood gas analysis, if correctly interpreted, could be an optimal tool to target therapeutic choices for cardiac arrest victims. Further studies with a higher sample size will be needed to validate this data.
- Published
- 2023
- Full Text
- View/download PDF
3. Drucebo effect in statin therapy: more attributable to the patient, the doctor, or the mass media?
- Author
-
D Cosmi, S D'Orazio, B Mariottoni, B Tarquini, and F Cosmi
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
In recent years, the term “drucebo effect” (drug + nocebo) has been coined to mean the nocebo effect attributable more to the patient's expectations, the doctor's preferences and the interference of the mass media rather than the actual pharmacological effect [1,2]. We evaluated this effect over the last 10 years in 9,605 outpatients treated with statins, in primary (27%) and secondary (73%) prevention. Statin intolerance was reported in 1,729 patients (18%) with discontinuation of therapy for 5 days to 4 weeks. The table shows the causes of the presumed intolerance. In patients with muscular symptoms we calculated the related SMIS (Statin Myalgia Index Score) [3]. Patients with myalgia with or without CPK elevation and probable or possible SMIS were advised to halve the statin dose and reassess after 2–4 weeks. With persisting symptoms, the statin was changed. If symptoms persisted also with the second statin, the patient was advised to take the drug every other day. In case of unlikely SMIS, the decision to resume statin therapy was shared with the patients, with an accurate counseling, informing them of the important benefits of statins regarding mortality and morbidity. Probable true statin intolerance was found in 576 patients (6% of the overall statin therapy population: 332 with myalgia with or without CPK elevation and SMIS probable, 152 with myalgia and CPK elevation with SMIS possible, 46 with asymptomatic elevation of CPK, 15 transaminases increase, 21 with general malaise, 10 with severe depression). In 12% of patients, on the other hand, the interruption is attributable to a nocebo effect due both to the patient and both to the treating physician or other specialist, inclined to attribute the unwanted symptoms more to the drug than to other factors or to consider it non-modifiable by changing statin or doses. The Influence of the mass media is significant, too, and it is difficult to distinguish a greater responsibility of one or the other. Conclusions in patients treated with statins a drucebo effect is attributable in part to the patient, in part to the doctor and to the mass media, which tend to attribute the symptoms (especially of muscle origin) to the treatment and to interrupt the therapy without take into account the clear benefits regarding reduction of mortality and morbidity [4]. In our study, a probable true intolerance to statins is found in about one third of patients who report symptoms of a presumed intolerance. Funding Acknowledgement Type of funding sources: None.
- Published
- 2022
- Full Text
- View/download PDF
4. P187 DRUCEBO EFFECT IN STATIN THERAPY: MORE ATTRIBUTABLE TO THE PATIENT, THE DOCTOR, OR THE MASS MEDIA?
- Author
-
D Cosmi, S D‘Orazio, B Mariottoni, B Tarquini, and F Cosmi
- Subjects
Cardiology and Cardiovascular Medicine - Abstract
In recent years, the term “drucebo effect” (drug + nocebo) has been coined to mean the nocebo effect attributable more to the patient‘s expectations, the doctor‘s preferences and the interference of the mass media rather than the actual pharmacological effect . We evaluated this effect in 9,605 patients treated with statins, in primary (27%) and secondary (73%) prevention. Presumed statin intolerance was reported in 1,729 patients (18%) with discontinuation of therapy for 5 days to 4 weeks. Table 1 shows the causes of the presumed intolerance and the related SMIS (Statin Myalgia Index Score). Patients with myalgia with or without CPK elevation and probable or possible SMIS were advised to halve the dose, with reassessment after 2–4 weeks. With persisting symptoms, the statin was changed. If symptoms were also present with the second statin, the patient was advised to take the drug every other day. In patients with unlikely SMIS, the decision to resume therapy was shared with the patient, informing him of the benefits of statins on mortality and morbidity. Probable true intolerance was found in 576 patients (6% of the overall population on statin therapy: 332 with myalgia with or without CPK elevation and SMIS probable, 152 with myalgia and CPK elevation with SMIS possible, 46 with asymptomatic CPK elevation, 15 transaminase increased, 21 with general malaise, 10 with severe depression). In 12% of patients, on the other hand, the interruption is attributable to a nocebo effect due to both the patient and the treating physician or other specialist, who are inclined to attribute the unwanted symptoms more to the drug than to other factors or to consider it non–modifiable by modifying the drug or the doses. Interference from the mass media is common, and it is difficult to distinguish a greater responsibility of one or the other.In patients treated with statins, a drucebo effect is frequently found, which is partly attributable to the patient, partly to the doctor and the mass media, who tend to attribute muscle symptoms to the treatment with statins and to interrupt therapy without taking into account the benefits regarding the reduction of mortality and morbidity found in numerous studies with indisputable evidence of efficacy and safety. In our study, a probable true intolerance to statins is found in about one third of patients who report symptoms.
- Published
- 2022
- Full Text
- View/download PDF
5. P126 - Mise en œuvre d'un indicateur de proximité et d'intensité aux expositions agricoles de riverains de parcelles agricoles en France: une méthode simple, valide et utilisable pour la recherche des facteurs de risque en cancérologie
- Author
-
S. Orazio, M. Gombert, and B. Vacquier
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health - Published
- 2023
- Full Text
- View/download PDF
6. Dexamethasone in acute cardiopulmonary syndrome with hyperinflammatory state
- Author
-
Deborah Cosmi, Franco Cosmi, P. Angori, Beatrice Mariottoni, and S. D'Orazio
- Subjects
business.industry ,medicine.drug_class ,ADRENAL CORTICOSTEROIDS ,Inflammatory response ,Antibiotics ,Procalcitonin ,Pharmacotherapy ,Immunology ,Medicine ,Hyperinflammatory state ,Cardiology and Cardiovascular Medicine ,business ,Dexamethasone ,medicine.drug - Abstract
Introduction Elderly patient hospitalized due to acute heart failure often have a concomitant acute lung disease (acute bronchitis, pneumonia, chronic obstructive pulmonary disease-COPD- exacerbation). Establishing the role of each disease in a clinical picture of acute cardiopulmonary syndrome can be challenging. Procalcitonin has been used as a guide to antibiotic therapy with contrasting results. A common thread of these diseases is inflammation; a hyperinflammatory response determines more serious symptoms and a worse prognosis. Purpose We evaluated the effectiveness of a treatment with dexamethasone in patients with acute cardiopulmonary syndrome and a strong inflammatory response. Materials and methods We evaluated 157 consecutive HFPEF (heart failure with preserved ejection fraction) patients ≥80 years of age, with concomitant symptoms attributable to acute bronchitis, pneumonia, or COPD exacerbation, hospitalized due to worsening dyspnoea, with an NT-proBNP ≥3,000 pg/ml, and a finding X-ray of lung congestion with or without a consolidation. Reactive C Protein was measured. Patients with SARS-CoV-2, indication to corticosteroids use for other clinical conditions or need for mechanical ventilation were excluded. The 96 patients with values>20 mg/dl were randomized into 2 groups: 48 patients were treated open-label with dexamethasone at a dose of 8 mg iv/day for a maximun of ten days, in addition to the usual therapies for acute heart failure and lung disease, while the same number of patients were treated with the usual therapy. In both groups the antibiotic was administered only if the procalcitonin was≥0.25 μg/L. Clinical recovery time, length of hospitalization, in-hospital mortality, the need for a new hospitalization and mortality at one month were evaluated. Results The mean age of the patients was 88±4 years in the dexamethasone group and 87±5 in the usual therapy group. The results are shown in Table 1. Patients treated with dexamethasone experienced a faster clinical recovery and a shorter length of hospitalization. No significant differences were found regarding either in-hospital mortality or need for rehospitalization and mortality at 30 days. Conclusions Very elderly patients with acute cardiopulmonary syndrome and hyperinflammatory state associated with an excessive increase in Reactive Protein C have a favorable response to dexamethasone therapy in addition to the usual therapy in terms of clinical improvement and length of hospitalization. Our case history is small to evaluate a possible improvement in mortality. These findings need to be consolidated from double-blind randomized controlled trials Funding Acknowledgement Type of funding sources: None. Table 1
- Published
- 2021
- Full Text
- View/download PDF
7. Increased incidence of pathogenic variants in ATM in the context of testing for breast and ovarian cancer predisposition
- Author
-
P, Macquere, S, Orazio, F, Bonnet, N, Jones, V, Bubien, J, Chiron, D, Lafon, E, Barouk-Simonet, J, Tinat, L, Venat-Bouvet, P, Gesta, M, Longy, and N, Sevenet
- Subjects
BRCA2 Protein ,Ovarian Neoplasms ,Incidence ,Hereditary Breast and Ovarian Cancer Syndrome ,Humans ,Breast Neoplasms ,Female ,Genetic Predisposition to Disease ,Ataxia Telangiectasia Mutated Proteins ,Genetic Testing - Abstract
Pathogenic Variants (PV) in major cancer predisposition genes are only identified in approximately 10% of patients with Hereditary Breast and Ovarian Cancer (HBOC) syndrome. Next Generation Sequencing (NGS) leads to the characterization of incidental variants in genes other than those known to be associated with HBOC syndrome. The aim of this study was to determine if such incidental PV were specific to a phenotype. The detection rates of HBOC-associated and incidental PV in 1812 patients who underwent genetic testing were compared with rates in control groups FLOSSIES and ExAC. The rates of incidental PV in the PALB2, ATM and CHEK2 genes were significantly increased in the HBOC group compared to controls with, respective odds ratios of 15.2 (95% CI = 5.6-47.6), 9.6 (95% CI = 4.8-19.6) and 2.7 (95% CI = 1.3-5.5). Unsupervised Hierarchical Clustering on Principle Components characterized 3 clusters: by HBOC (P = 0.01); by ExAC and FLOSSIES (P = 0.01 and 0.02 respectively); and by HBOC, ExAC and FLOSSIES (P = 0.01, 0.04 and 0.04 respectively). Interestingly, PALB2 and ATM were grouped in the same statistical cluster defined by the HBOC group, whereas CHEK2 was in a different cluster. We identified co-occurrences of PV in ATM and BRCA genes and confirmed the Manchester Scoring System as a reliable PV predictor tool for BRCA genes but not for ATM or PALB2. This study demonstrates that ATM PV, and to a lesser extent CHEK2 PV, are associated with HBOC syndrome. The co-occurrence of ATM PV with BRCA PV suggests that such ATM variants are not sufficient alone to induce cancer, supporting a multigenism hypothesis.
- Published
- 2021
8. La survie sans événement à 24 mois comme indicateur pronostique précoce chez des patients atteints de lymphome diffus à grandes cellules B : validation et utilisation en population générale
- Author
-
S. Leguyader-Peyrou, S. Orazio, and Alain Monnereau
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health - Abstract
Introduction Sur la base d’observations issues de cohortes cliniques, M.J. Maurer a propose d’utiliser la survie sans evenement (rechute, remise en traitement, deces) a 24 mois (EFS-24) comme indicateur pronostique precoce des patients atteints de Lymphome dffus a grandes cellules B (LDGCB) traites par immuno-chimiotherapie. Cependant, la methode de validation de l’indicateur fait debat, et n’a jamais ete utilisee sur des cohortes de patients non selectionnees c’est-a-dire issues de la population generale. Nous proposons dans cette etude de : – Tester et valider l’EFS-24 en population generale a partir des donnees des registres de cancers ; – Valider l’indicateur en utilisant les dernieres methodes d’estimation de la survie nette. Methodes La population d’etude est constituee de 1312 cas de lymphome diffus a grandes cellules B diagnostiques sur la periode 2002-2008 par trois registres de cancers francais specialises sur les hemopathies malignes (Basse-Normandie, Cote d’Or et Gironde). Nous proposons de valider l’EFS-24 a partir d’un modele du taux de mortalite en exces. Les analyses sont realisees avec le package R mexhaz. Resultats Sur 615 patients ayant recu une premiere ligne de traitement par R-CHOP, 65 % d’entre eux ont atteint l’EFS-24. Le suivi median des patients de la cohorte est de 10 ans. Le modele final retenu comprend les variables suivantes : AGE (> 70 ans ou non), EFS-24 (Atteinte ou non), IPI (0-2 versus 3-5) et ACE27 (pas ou peu versus moderees a severes). L’âge et l’EFS-24 sont modelises avec des effets non proportionnels au cours du temps. La Fig. 1 (A) montre que les patients sans evenement a 24 mois et ayant des caracteristiques defavorables (ACE27 2-3, IPI 3-5, âge > 70 ans) ont une mortalite en exces plus elevee que celle estimee pour les patients ayant connu un evenement dans les 24 mois apres le diagnostic ayant des caracteristiques plutot favorables (ACE27 0-1, IPI 0-2, âge ≤ 70 ans), des 30 mois apres le diagnostic. Cela se traduit par une survie nette des deux groupes des patients comparable 10 ans apres le diagnostic ( Fig. 1 (B)). Conclusion Notre etude en population generale montre que l’utilisation de l’indicateur precoce de survie sans evenement a 24 mois est un indicateur pronostique precoce valide uniquement chez un sous-groupe favorable des patients traites par R-CHOP et atteints de LDGCB (jeunes, sans comorbidite avec un index pronostique favorable).
- Published
- 2021
- Full Text
- View/download PDF
9. Global surveillance of trends in cancer survival 2000-14 (concord-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- Author
-
Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, S Bouzbid, M Hamdi-Chérif, Z Zaidi, K Meguenni, D Regagba, S Bayo, T Cheick Bougadari, S S Manraj, A Fabowale, O J Ogunbiyi, D Bradshaw, N I M Somdyala, I Kumcher, F Moreno, G H Calabrano, S B Espinola, B Carballo Quintero, R Fita, M C Diumenjo, W D Laspada, S G Ibañez, C A Lima, P C F De Souza, K Del Pino, C Laporte, M P Curado, J C de Oliveira, C L A Veneziano, D B Veneziano, M R D O Latorre, L F Tanaka, M S Rebelo, M O Santos, G Azevedo e Silva, J C Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D A Herrmann, S Vargas, V M Herrera, C J Uribe, L E Bravo, L S Garcia, N E Arias-Ortiz, D Morantes, D M Jurado, M C Yépez Chamorro, S Delgado, M Ramirez, Y H Galán Alvarez, P Torres, F Martínez-Reyes, L Jaramillo, R Quinto, J, M Mendoza, P Cueva, J G Yépez, B Bhakkan, J Deloumeaux, C Joachim, J Macni, R Carrillo, J Shalkow Klincovstein, R Rivera Gomez, E Poquioma, G Tortolero-Luna, D Zavala, R Alonso, E Barrios, A Eckstrand, C Nikiforuk, R R Woods, G Noonan, D Turner, E Kumar, B Zhang, F R McCrate, S Ryan, M MacIntyre, N Saint-Jacques, D E Nishri, C A McClure, K A Vriends, S Kozie, H Stuart-Panko, T Freeman, J T George, J T Brockhouse, D K O'Brien, A Holt, L Almon, S Kwong, C Morris, R Rycroft, L Mueller, C E Phillips, H Brown, B Cromartie, A G Schwartz, F Vigneau, G M Levin, B Wohler, R Bayakly, K C Ward, S L Gomez, M McKinley, R Cress, M D Green, K Miyagi, C J Johnson, L P Ruppert, C F Lynch, B Huang, T C Tucker, D Deapen, L Liu, M C Hsieh, X C Wu, M Schwenn, S T Gershman, R C Knowlton, G Alverson, G E Copeland, S Bushhouse, D B Rogers, J Jackson-Thompson, D Lemons, H J Zimmerman, M Hood, J Roberts-Johnson, J R Rees, B Riddle, K S Pawlish, A Stroup, C Key, C Wiggins, A R Kahn, M J Schymura, S Radhakrishnan, C Rao, L K Giljahn, R M Slocumb, R E Espinoza, F Khan, K G Aird, T Beran, J J Rubertone, S J Slack, L Garcia, D L Rousseau, T A Janes, S M Schwartz, S W Bolick, D M Hurley, M A Whiteside, P Miller-Gianturco, M A Williams, K Herget, C Sweeney, A T Johnson, M B Keitheri Cheteri, P Migliore Santiago, S E Blankenship, S Farley, R Borchers, R Malicki, J R Espinoza, J Grandpre, H K Weir, R Wilson, B K Edwards, A Mariotto. Y Lei, N Wang, J S Chen, Y Zhou, Y T He, G H Song, X P Gu, D Mei, H J Mu, H M Ge, T H Wu, Y Y Li, D L Zhao, F Jin, J H Zhang, F D Zhu, Q Junhua, Y L Yang, C X Jiang, W Biao, J Wang, Q L Li, H Yi, X Zhou, J Dong, W Li, F X Fu, S Z Liu, J G Chen, J Zhu, Y H Li, Y Q Lu, M Fan, S Q Huang, G P Guo, H Zhaolai, K Wei, W Q Chen, H Zeng, A V Demetriou, W K Mang, K C Ngan, A C Kataki, M Krishnatreya, P A Jayalekshmi, P Sebastian, A Nandakumar, R Malekzadeh, G Roshandel, L Keinan-Boker, B G Silverman, H Ito, H Nakagawa, M Sato, F Tobori, I Nakata, N Teramoto, M Hattori, Y Kaizaki, F Moki, H Sugiyama, M Utada, M Nishimura, K Yoshida, K Kurosawa, Y Nemoto, H Narimatsu, M Sakaguchi, S Kanemura, M Naito, R Narisawa, I Miyashiro, K Nakata, S Sato, M Yoshii, I Oki, N Fukushima, A Shibata, K Iwasa, C Ono, T Matsuda, O Nimri, K W Jung, Y J Won, E Alawadhi, A Elbasmi, A Ab Manan, F Adam, E Sanjaajmats, U Tudev, C Ochir, A M Al Khater, M M El Mistiri, G H Lim, Y Y Teo, C J Chiang, W C Lee, R Buasom, S Sangrajrang, S Kamsaard, S Wiangnon, K Daoprasert, D Pongnikorn, A Leklob, S Sangkitipaiboon, S L Geater, H Sriplung, O Ceylan, I Kög, O Dirican, T Köse, T Gurbuz, F E Karaşahin, D Turhan, U Aktaş, Y Halat, S Eser, C I Yakut, M Altinisik, Y Cavusoglu, A Türkköylü, N Üçüncü, M Hackl, A A Zborovskaya, O V Aleinikova, K Henau, L Van Eycken, Z Valerianova, M R Yordanova, M Šekerija, L Dušek, M Zvolský, G Engholm, H Storm, K Innos, M Mägi, N Malila, K Seppä, J Jégu, M Velten, E Cornet, X Troussard, A M Bouvier, A V Guizard, V Bouvier, G Launoy, P Arveux, M Maynadié, M Mounier, A S Worono, M Daoulas, M Robaszkiewicz, J Clavel, S Goujon, B Lacour, I Baldi, C Pouchieu, B Amadeo, G Coureau, A Monnereau, S Orazio, P M Preux, F Rharbaoui, E Marrer, B Trétarre, M Colonna, P Delafosse, K Ligier, S Plouvier, A Cowppli-Bony, F Molinié, S Bara, O Ganry, B Lapôtre- Ledoux, P Grosclaude, N Bossard, Z Uhry, F Bray, M Piñeros, J Estève, R Stabenow, H Wilsdorf-Köhler, A Eberle, S Luttmann, I Löhden, A L Nennecke, J Kieschke, E Sirri, K Emrich, S R Zeissig, B Holleczek, N Eisemann, A Katalinic, R A Asquez, V Kumar, E Petridou, E J Ólafsdóttir, L Tryggvadóttir, K Clough-Gorr, P M Walsh, H Sundseth, G Mazzoleni, F Vittadello, E Coviello, F Cuccaro, R Galasso, G Sampietro, A Giacomin, M Magoni, A Ardizzone, A D'Argenzio, M Castaing, G Grosso, A M Lavecchia, A Sutera Sardo, G Gola, L Gatti, P Ricci, S Ferretti, D Serraino, A Zucchetto, M V Celesia, R A Filiberti, F Pannozzo, A Melcarne, F Quarta, A G Russo, G Carrozzi, C Cirilli, L Cavalieri d'Oro, M Rognoni, M Fusco, M F Vitale, M Usala, R Cusimano, W Mazzucco, M Michiara, P Sgargi, L Boschetti, E Borciani, P Seghini, M M Maule, F Merletti, R Tumino, P Mancuso, M Vicentini, T Cassetti, R Sassatelli, F Falcini, S Giorgetti, A L Caiazzo, R Cavallo, R Cesaraccio, D R Pirino, M L Contrino, F Tisano, A C Fanetti, S Maspero, S Carone, A Mincuzzi, G Candela, T Scuderi, M A Gentilini, S Pier, S Rosso, A Barchielli, A Caldarella, F Bianconi, F Stracci, P Contiero, G Tagliabue, M Rugge, M Zorzi, S Beggiato, A Brustolin, F Berrino, G Gatta, M Sant, C Buzzoni, L Mangone, R Capocaccia, R De Angelis, R Zanetti, A Maurina, S Pildava, N Lipunova, I Vincerževskienė, D Agius, N Calleja, S Siesling, O Visser, Larønningen, B Møller, A Dyzmann-Sroka, M Trojanowski, S Góźdź, R Mężyk, T Mierzwa, L Molong, J Rachtan, S Szewczyk, J Błaszczyk, K Kępska, B Kościańska, K Tarocińska, M Zwierko, K Drosik, K M Maksimowicz, E Purwin-Porowska, E Reca, J Wójcik-Tomaszewska, A Tukiendorf, M Grądalska-Lampart, A U Radziszewska, A Gos, M Talerczyk, M Wyborska, J A Didkowska, U Wojciechowska, M Bielska-Lasota, G Forjaz de Lacerda, R A Rego, J Bastos, M A Silva, L Antunes, J Laranja Pontes, A Mayer-da-Silva, A Miranda, L M Blaga, D Coza, Russia: M Y Valkov, L Gusenkova, O Lazarevich, O Prudnikova, D M Vjushkov, A G Egorova, A E Orlov, L A Kudyakov, L V Pikalova, J Adamcik, C Safaei Diba, M Primic-Žakelj, V Zadnik, N Larrañaga, A Lopez de Munain, A A Herrera, R Redondas, R Marcos-Gragera, M L Vilardell Gil, E Molina, M J Sánchez Perez, P Franch Sureda, M Ramos Montserrat, M D Chirlaque, C Navarro, E E Ardanaz, M M Guevara, R Fernández-Delgado, R Peris-Bonet, M Carulla, J Galceran, C Alberich, M Vicente-Raneda, S Khan, D Pettersson, P Dickman, I Avelina, K Staehelin, B Camey, C Bouchardy, R Schaar, H Frick, C Herrmann, J L Bulliard, M Maspoli-Conconi, C E Kuehni, S M Redmond, A Bordoni, L Ortelli, A Chiolero, I Konzelmann, K L Matthes, S Rohrmann, Broggio, J Rashbass, D Fitzpatrick, A Gavin, D I Clark, A J Deas, D W Huws, C White, C Allemani, A Bonaventure, M P Coleman, V Di Carlo, R Harewood, M Matz, L Montel, M Nikšić, B Rachet, A D Turculeț, R Stephens, C A Stiller, E Chalker, H Phung, R Walton, H You, S Guthridge, F Johnson, J Aitken, P Gordon, K D'Onise, K Priest, B C Stokes, A Venn, H Farrugia, V Thurs eld, J Dowlin, D Currow, J Hendrix, C Lewis, Tıp Fakültesi, Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Claudia Allemani, Tomohiro Matsuda, Veronica Di Carlo, Rhea Harewood, Melissa Matz, Maja Nikšić, Audrey Bonaventure, Mikhail Valkov, Christopher J Johnson, Jacques Estève, Olufemi J Ogunbiyi, Gulnar Azevedo e Silva, Wan-Qing Chen, Sultan Eser, Gerda Engholm, Charles A Stiller, Alain Monnereau, Ryan R Woods, Otto Visser, Gek Hsiang Lim, Joanne Aitken, Hannah K Weir, Michel P Coleman, S Bouzbid, M Hamdi-Chérif, Z Zaidi, K Meguenni, D Regagba, S Bayo, T Cheick Bougadari, S S Manraj, A Fabowale, O J Ogunbiyi, D Bradshaw, N I M Somdyala, I Kumcher, F Moreno, G H Calabrano, S B Espinola, B Carballo Quintero, R Fita, M C Diumenjo, W D Laspada, S G Ibañez, C A Lima, P C F De Souza, K Del Pino, C Laporte, M P Curado, J C de Oliveira, C L A Veneziano, D B Veneziano, M R D O Latorre, L F Tanaka, M S Rebelo, M O Santos, G Azevedo e Silva, J C Galaz, M Aparicio Aravena, J Sanhueza Monsalve, D A Herrmann, S Vargas, V M Herrera, C J Uribe, L E Bravo, L S Garcia, N E Arias-Ortiz, D Morantes, D M Jurado, M C Yépez Chamorro, S Delgado, M Ramirez, Y H Galán Alvarez, P Torres, F Martínez-Reyes, L Jaramillo, R Quinto, J, M Mendoza, P Cueva, J G Yépez, B Bhakkan, J Deloumeaux, C Joachim, J Macni, R Carrillo, J Shalkow Klincovstein, R Rivera Gomez, E Poquioma, G Tortolero-Luna, D Zavala, R Alonso, E Barrios, A Eckstrand, C Nikiforuk, R R Woods, G Noonan, D Turner, E Kumar, B Zhang, F R McCrate, S Ryan, M MacIntyre, N Saint-Jacques, D E Nishri, C A McClure, K A Vriends, S Kozie, H Stuart-Panko, T Freeman, J T George, J T Brockhouse, D K O'Brien, A Holt, L Almon, S Kwong, C Morris, R Rycroft, L Mueller, C E Phillips, H Brown, B Cromartie, A G Schwartz, F Vigneau, G M Levin, B Wohler, R Bayakly, K C Ward, S L Gomez, M McKinley, R Cress, M D Green, K Miyagi, C J Johnson, L P Ruppert, C F Lynch, B Huang, T C Tucker, D Deapen, L Liu, M C Hsieh, X C Wu, M Schwenn, S T Gershman, R C Knowlton, G Alverson, G E Copeland, S Bushhouse, D B Rogers, J Jackson-Thompson, D Lemons, H J Zimmerman, M Hood, J Roberts-Johnson, J R Rees, B Riddle, K S Pawlish, A Stroup, C Key, C Wiggins, A R Kahn, M J Schymura, S Radhakrishnan, C Rao, L K Giljahn, R M Slocumb, R E Espinoza, F Khan, K G Aird, T Beran, J J Rubertone, S J Slack, L Garcia, D L Rousseau, T A Janes, S M Schwartz, S W Bolick, D M Hurley, M A Whiteside, P Miller-Gianturco, M A Williams, K Herget, C Sweeney, A T Johnson, M B Keitheri Cheteri, P Migliore Santiago, S E Blankenship, S Farley, R Borchers, R Malicki, J R Espinoza, J Grandpre, H K Weir, R Wilson, B K Edwards, A Mariotto. Y Lei, N Wang, J S Chen, Y Zhou, Y T He, G H Song, X P Gu, D Mei, H J Mu, H M Ge, T H Wu, Y Y Li, D L Zhao, F Jin, J H Zhang, F D Zhu, Q Junhua, Y L Yang, C X Jiang, W Biao, J Wang, Q L Li, H Yi, X Zhou, J Dong, W Li, F X Fu, S Z Liu, J G Chen, J Zhu, Y H Li, Y Q Lu, M Fan, S Q Huang, G P Guo, H Zhaolai, K Wei, W Q Chen, H Zeng, A V Demetriou, W K Mang, K C Ngan, A C Kataki, M Krishnatreya, P A Jayalekshmi, P Sebastian, A Nandakumar, R Malekzadeh, G Roshandel, L Keinan-Boker, B G Silverman, H Ito, H Nakagawa, M Sato, F Tobori, I Nakata, N Teramoto, M Hattori, Y Kaizaki, F Moki, H Sugiyama, M Utada, M Nishimura, K Yoshida, K Kurosawa, Y Nemoto, H Narimatsu, M Sakaguchi, S Kanemura, M Naito, R Narisawa, I Miyashiro, K Nakata, S Sato, M Yoshii, I Oki, N Fukushima, A Shibata, K Iwasa, C Ono, T Matsuda, O Nimri, K W Jung, Y J Won, E Alawadhi, A Elbasmi, A Ab Manan, F Adam, E Sanjaajmats, U Tudev, C Ochir, A M Al Khater, M M El Mistiri, G H Lim, Y Y Teo, C J Chiang, W C Lee, R Buasom, S Sangrajrang, S Kamsaard, S Wiangnon, K Daoprasert, D Pongnikorn, A Leklob, S Sangkitipaiboon, S L Geater, H Sriplung, O Ceylan, I Kög, O Dirican, T Köse, T Gurbuz, F E Karaşahin, D Turhan, U Aktaş, Y Halat, S Eser, C I Yakut, M Altinisik, Y Cavusoglu, A Türkköylü, N Üçüncü, M Hackl, A A Zborovskaya, O V Aleinikova, K Henau, L Van Eycken, Z Valerianova, M R Yordanova, M Šekerija, L Dušek, M Zvolský, G Engholm, H Storm, K Innos, M Mägi, N Malila, K Seppä, J Jégu, M Velten, E Cornet, X Troussard, A M Bouvier, A V Guizard, V Bouvier, G Launoy, P Arveux, M Maynadié, M Mounier, A S Worono, M Daoulas, M Robaszkiewicz, J Clavel, S Goujon, B Lacour, I Baldi, C Pouchieu, B Amadeo, G Coureau, A Monnereau, S Orazio, P M Preux, F Rharbaoui, E Marrer, B Trétarre, M Colonna, P Delafosse, K Ligier, S Plouvier, A Cowppli-Bony, F Molinié, S Bara, O Ganry, B Lapôtre- Ledoux, P Grosclaude, N Bossard, Z Uhry, F Bray, M Piñeros, J Estève, R Stabenow, H Wilsdorf-Köhler, A Eberle, S Luttmann, I Löhden, A L Nennecke, J Kieschke, E Sirri, K Emrich, S R Zeissig, B Holleczek, N Eisemann, A Katalinic, R A Asquez, V Kumar, E Petridou, E J Ólafsdóttir, L Tryggvadóttir, K Clough-Gorr, P M Walsh, H Sundseth, G Mazzoleni, F Vittadello, E Coviello, F Cuccaro, R Galasso, G Sampietro, A Giacomin, M Magoni, A Ardizzone, A D'Argenzio, M Castaing, G Grosso, A M Lavecchia, A Sutera Sardo, G Gola, L Gatti, P Ricci, S Ferretti, D Serraino, A Zucchetto, M V Celesia, R A Filiberti, F Pannozzo, A Melcarne, F Quarta, A G Russo, G Carrozzi, C Cirilli, L Cavalieri d'Oro, M Rognoni, M Fusco, M F Vitale, M Usala, R Cusimano, W Mazzucco, M Michiara, P Sgargi, L Boschetti, E Borciani, P Seghini, M M Maule, F Merletti, R Tumino, P Mancuso, M Vicentini, T Cassetti, R Sassatelli, F Falcini, S Giorgetti, A L Caiazzo, R Cavallo, R Cesaraccio, D R Pirino, M L Contrino, F Tisano, A C Fanetti, S Maspero, S Carone, A Mincuzzi, G Candela, T Scuderi, M A Gentilini, S Pier, S Rosso, A Barchielli, A Caldarella, F Bianconi, F Stracci, P Contiero, G Tagliabue, M Rugge, M Zorzi, S Beggiato, A Brustolin, F Berrino, G Gatta, M Sant, C Buzzoni, L Mangone, R Capocaccia, R De Angelis, R Zanetti, A Maurina, S Pildava, N Lipunova, I Vincerževskienė, D Agius, N Calleja, S Siesling, O Visser, Larønningen, B Møller, A Dyzmann-Sroka, M Trojanowski, S Góźdź, R Mężyk, T Mierzwa, L Molong, J Rachtan, S Szewczyk, J Błaszczyk, K Kępska, B Kościańska, K Tarocińska, M Zwierko, K Drosik, K M Maksimowicz, E Purwin-Porowska, E Reca, J Wójcik-Tomaszewska, A Tukiendorf, M Grądalska-Lampart, A U Radziszewska, A Gos, M Talerczyk, M Wyborska, J A Didkowska, U Wojciechowska, M Bielska-Lasota, G Forjaz de Lacerda, R A Rego, J Bastos, M A Silva, L Antunes, J Laranja Pontes, A Mayer-da-Silva, A Miranda, L M Blaga, D Coza, Russia: M Y Valkov, L Gusenkova, O Lazarevich, O Prudnikova, D M Vjushkov, A G Egorova, A E Orlov, L A Kudyakov, L V Pikalova, J Adamcik, C Safaei Diba, M Primic-Žakelj, V Zadnik, N Larrañaga, A Lopez de Munain, A A Herrera, R Redondas, R Marcos-Gragera, M L Vilardell Gil, E Molina, M J Sánchez Perez, P Franch Sureda, M Ramos Montserrat, M D Chirlaque, C Navarro, E E Ardanaz, M M Guevara, R Fernández-Delgado, R Peris-Bonet, M Carulla, J Galceran, C Alberich, M Vicente-Raneda, S Khan, D Pettersson, P Dickman, I Avelina, K Staehelin, B Camey, C Bouchardy, R Schaar, H Frick, C Herrmann, J L Bulliard, M Maspoli-Conconi, C E Kuehni, S M Redmond, A Bordoni, L Ortelli, A Chiolero, I Konzelmann, K L Matthes, S Rohrmann, Broggio, J Rashbass, D Fitzpatrick, A Gavin, D I Clark, A J Deas, D W Huws, C White, C Allemani, A Bonaventure, M P Coleman, V Di Carlo, R Harewood, M Matz, L Montel, M Nikšić, B Rachet, A D Turculeț, R Stephens, C A Stiller, E Chalker, H Phung, R Walton, H You, S Guthridge, F Johnson, J Aitken, P Gordon, K D'Onise, K Priest, B C Stokes, A Venn, H Farrugia, V Thurs eld, J Dowlin, D Currow, J Hendrix, C Lewis
- Subjects
0301 basic medicine ,Universal Health Coverage ,population-based registries ,Relative Survival ,Settore MED/42 - Igiene Generale E Applicata ,Cancer -- Treatment ,Humans ,Neoplasms ,Population Surveillance ,Registries ,Survival Rate ,Medicine (all) ,0302 clinical medicine ,cancer survival ,education.field_of_study ,Relative survival ,EPICENE ,General Medicine ,3. Good health ,trend ,030220 oncology & carcinogenesis ,Public-Health ,cancer surveillance ,Liver cancer ,survival ,cancer registry ,CONCORD-3 ,Cure ,Childhood-Cancer ,medicine.medical_specialty ,population-based cancer registries ,Womens Cancers ,Population ,Medicine (all),cancer survival, population-based cancer registries ,Socio-culturale ,United-States ,Article ,03 medical and health sciences ,Breast cancer ,Cancer epidemiology ,medicine ,Nordic-Countries ,Cancer -- Mortality ,education ,Survival rate ,Cancer prevention ,Alternative Approach ,business.industry ,Public health ,Cancer ,Cancer -- Patients -- Long-term care ,medicine.disease ,030104 developmental biology ,High-Income Countries ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,business ,Demography - Abstract
Eser, Sultan (Balikesir Author), Background In 2015, the second cycle of the CONCORD programme established global surveillance of cancer survival as a metric of the effectiveness of health systems and to inform global policy on cancer control. CONCORD-3 updates the worldwide surveillance of cancer survival to 2014. Methods CONCORD-3 includes individual records for 37.5 million patients diagnosed with cancer during the 15-year period 2000-14. Data were provided by 322 population-based cancer registries in 71 countries and territories, 47 of which provided data with 100% population coverage. The study includes 18 cancers or groups of cancers: oesophagus, stomach, colon, rectum, liver, pancreas, lung, breast (women), cervix, ovary, prostate, and melanoma of the skin in adults, and brain tumours, leukaemias, and lymphomas in both adults and children. Standardised quality control procedures were applied; errors were rectified by the registry concerned. We estimated 5-year net survival. Estimates were age-standardised with the International Cancer Survival Standard weights.Findings For most cancers, 5-year net survival remains among the highest in the world in the USA and Canada, in Australia and New Zealand, and in Finland, Iceland, Norway, and Sweden. For many cancers, Denmark is closing the survival gap with the other Nordic countries. Survival trends are generally increasing, even for some of the more lethal cancers: in some countries, survival has increased by up to 5% for cancers of the liver, pancreas, and lung. For women diagnosed during 2010-14, 5-year survival for breast cancer is now 89.5% in Australia and 90.2% in the USA, but international differences remain very wide, with levels as low as 66.1% in India. For gastrointestinal cancers, the highest levels of 5-year survival are seen in southeast Asia: in South Korea for cancers of the stomach (68.9%), colon (71.8%), and rectum (71.1%); in Japan for oesophageal cancer (36.0%); and in Taiwan for liver cancer (27.9%). By contrast, in the same world region, survival is generally lower than elsewhere for melanoma of the skin (59.9% in South Korea, 52.1% in Taiwan, and 49.6% in China), and for both lymphoid malignancies (52.5%, 50.5%, and 38.3%) and myeloid malignancies (45.9%, 33.4%, and 24.8%). For children diagnosed during 2010-14, 5-year survival for acute lymphoblastic leukaemia ranged from 49.8% in Ecuador to 95.2% in Finland. 5-year survival from brain tumours in children is higher than for adults but the global range is very wide (from 28.9% in Brazil to nearly 80% in Sweden and Denmark). Interpretation The CONCORD programme enables timely comparisons of the overall effectiveness of health systems in providing care for 18 cancers that collectively represent 75% of all cancers diagnosed worldwide every year. It contributes to the evidence base for global policy on cancer control. Since 2017, the Organisation for Economic Co-operation and Development has used findings from the CONCORD programme as the official benchmark of cancer survival, among their indicators of the quality of health care in 48 countries worldwide. Governments must recognise population-based cancer registries as key policy tools that can be used to evaluate both the impact of cancer prevention strategies and the effectiveness of health systems for all patients diagnosed with cancer., American Cancer Society Centers for Disease Control and Prevention Swiss Re Swiss Cancer Research foundation Swiss Cancer League Institut National du Cancer La Ligue Contre le Cancer Rossy Family Foundation US National Cancer Institute Susan G Komen Foundation
- Published
- 2018
- Full Text
- View/download PDF
10. P2755Effectiveness of mechanical chest compression devices in cardiac arrest: a single centre, observational, prospective study
- Author
-
Nicola Gasparetto, P. Rosi, S. Orazio, A. De Leo, A. Forti, G. Zilio, Zoran Olivari, A. Daniotti, P. Martire, D. Calzolari, F. Marson, V. Salandin, and L. Favero
- Subjects
Single centre ,medicine.medical_specialty ,business.industry ,medicine ,Observational study ,Cardiology and Cardiovascular Medicine ,Intensive care medicine ,Compression (physics) ,Prospective cohort study ,business - Published
- 2017
- Full Text
- View/download PDF
11. Emploi d’un collier cervical souple dans l’apnée obstructive du sommeil, étude pilote
- Author
-
S. Orazio, A. Lataste, and P. Bordier
- Subjects
Behavioral Neuroscience ,Neuropsychology and Physiological Psychology ,Neurology ,Cognitive Neuroscience ,Neurology (clinical) - Abstract
Objectif Avant un essai randomise controle sur l’emploi d’un collier cervical souple dans l’apnee obstructive du sommeil (AOS), nous avons evalue dans une etude pilote : – la tolerance du collier chez des patients avec AOS ; – l’impact de ce support sur la permeabilite pharyngee dans l’AOS ; – le nombre d’inclusions necessaires a l’essai envisage pour des resultats solides. Methodes Vingt patients avec une AOS severe selon une 1re polygraphie ont ete randomises vers une 2e polygraphie soit sans intervention (groupe controle, n = 10) soit avec port du collier (groupe intervention, n = 10). Les resultats des polygraphies ont ete compares et la tolerance du collier a ete evaluee par un questionnaire. Resultats Quatorze hommes et six femmes, 53,3 ± 2,7 ans, 34,0 ± 0,3 kg/m2, ont ete etudies. En majorite, la tolerance du collier a ete bonne. Il n’y a pas eu de difference significative entre les resultats des 1re et 2e polygraphies dans chacun des deux groupes, e.g., l’index d’apnee-hypopnee etait de 57,8 ± 5,5 vs. 52,4 ± 7,2 (p = 0,4) dans le groupe controle et 56,6 ± 8,1 vs. 52,0 ± 8,4 (p = 0,39) dans le groupe intervention. L’evolution des resultats entre les deux polygraphies etaient semblables entre les deux groupes. Le nombre d’inclusions necessaires a l’essai envisage a ete calcule a 246 selon la methode du d de Cohen. Conclusion Cette etude pilote chez des patients avec AOS severe montre un collier cervical souple bien tolere et sans effet sur la permeabilite pharyngee. Un essai randomise controle plus large pour des resultats solides apparait realisable.
- Published
- 2019
- Full Text
- View/download PDF
12. Poster session II * Thursday 9 December 2010, 14:00-18:00
- Author
-
P. A. Pabari, A. Kyriacou, M. Moraldo, B. Unsworth, R. Baruah, N. Sutaria, A. Hughes, J. Mayet, D. P. Francis, T. Uejima, K. Loboz, F. Antonini-Canterin, C. Polombo, S. Carerj, D. Vinereanu, A. Evangelista, G. Leftheriotis, A. G. Fraser, A. Kiotsekoglou, M. Govindan, S. C. Govind, S. K. Saha, A. J. Camm, P. M. Azcarate, S. Castano, M. Rodriguez-Manero, M. Arraiza, B. Levy, J. Barba, G. Rabago, G. Bastarrika, A. Nemes, R. Takacs, T. Varkonyi, H. Gavaller, I. Baczko, T. Forster, T. Wittmann, J. G. Papp, C. Lengyel, A. Varro, L. R. Tumasyan, K. G. Adamyan, O. Savu, T. Mieghem, P. Dekoninck, L. Gucciardo, R. Jurcut, S. Giusca, B. A. Popescu, C. Ginghina, J. Deprest, J. U. Voigt, M. Versiero, M. Galderisi, R. Esposito, A. Rapacciuolo, G. Esposito, R. Raia, T. Morgillo, F. Piscione, G. De Simone, M. A. Oraby, F. A. Maklady, E. M. Mohamed, A. Z. Eraki, D. Zaliaduonyte-Peksiene, E. Tamuleviciute, J. Janenaite, J. Marcinkeviciene, V. Mizariene, S. Bucyte, J. Vaskelyte, D. Trifunovic, I. Nedeljkovic, D. Popovic, M. Ostojic, B. Vujisic-Tesic, M. Petrovic, S. Stankovic, D. Sobic-Saranovic, M. Banovic, A. Dikic-Djordjevic, K. Savino, A. Lilli, E. Grikstaite, V. Giglio, E. Bordoni, G. Maragoni, C. Cavallini, G. Ambrosio, B. Jakovljevic, B. Beleslin, M. Nedeljkovic, O. Petrovic, S. Moral, J. Rodriguez-Palomares, M. Descalzo, G. Marti, V. Pineda, P. Mahia, L. Gutierrez, T. Gonzalez-Alujas, D. Garcia-Dorado, F. Schnell, E. Donal, C. Thebault, A. Bernard, H. Corbineau, H. Le Breton, J. Kochanowski, P. Scislo, R. Piatkowski, M. Roik, M. Marchel, D. Kosior, G. Opolski, A. M. Lesniak-Sobelga, E. Wicher-Muniak, M. Kostkiewicz, M. Olszowska, E. Suchon, P. Klimeczek, P. Banys, M. Pasowicz, W. Tracz, P. Podolec, A. Laynez, D. E. Hoefsten, B. B. Loegstrup, B. Norager, J. E. Moller, A. Flyvbjerg, K. Egstrup, W. Streb, M. Szulik, J. Nowak, E. Markowicz-Pawlus, A. Duszanska, A. Sedkowska, Z. Kalarus, T. Kukulski, L. Spinelli, C. Morisco, E. Assante Di Panzillo, F. Buono, S. Crispo, B. Trimarco, A. A. Hawary, G. M. Nasr, M. M. Fawzy, L. Faber, W. Scholtz, J. Boergermann, M. Wiemer, G. Kleikamp, N. Bogunovic, Z. Dimitriadis, J. Gummert, D. Hering, D. Horstkotte, F. Luca', S. Gelsomino, R. Lorusso, S. Caciolli, R. Carella, G. Bille', G. De Cicco, V. Pazzagli, G. F. Gensini, A. Borowiec, R. Dabrowski, J. Janas, A. Kraska, B. Firek, I. Kowalik, H. Szwed, K. A. Marcus, C. L. De Korte, T. Feuth, J. M. Thijssen, L. Kapusta, J. Dahl, L. Videbaek, M. K. Poulsen, P. A. Pellikka, K. Veien, L. I. Andersen, T. Haghfelt, M. Haberka, K. Mizia - Stec, T. Adamczyk, M. Mizia, A. Chmiel, P. Pysz, M. Sosnowski, Z. Gasior, M. Trusz - Gluza, M. Tendera, T. Niklewski, K. Wilczek, P. Chodor, T. Podolecki, A. Frycz-Kurek, M. Zembala, S. Yurdakul, O. Yildirimturk, Y. Tayyareci, K. Memic, I. C. C. Demiroglu, S. Aytekin, C. J. Garcia Alonso, E. Ferrer Sistach, L. Delgado, J. Lopez Ayerbe, N. Vallejo Camazon, F. Gual Capllonch, M. Espriu Simon, X. Ruyra, A. Caballero Parrilla, A. Bayes Genis, L. Lecuyer, A. Berrebi, E. Florens, M. Noghin, C. Huerre, P. Achouh, R. Zegdi, J. N. Fabiani, B. De Chiara, A. Moreo, F. Musca, F. De Marco, E. Lobiati, O. Belli, F. Mauri, S. Klugmann, A. Caballero, N. Vallejo, A. Gonzalez Guardia, R. Nunez Aragon, C. Bosch, E. Ferrer, M. L. Pedro Botet, F. Gual, M. Cusma-Piccione, C. Zito, G. Oreto, R. Giuffre, M. C. Todaro, C. M. Barbaro, S. Lanteri, C. Longordo, J. Salvia, A. Bensaid, R. Gallet, E. Fougeres, P. Lim, J. Nahum, J. F. Deux, P. Gueret, E. Teiger, J. L. Dubois-Rande, J. L. Monin, F. Behramoglu, Z. Colakoglu, V. Aytekin, C. Demiroglu, L. Gargani, E. Poggianti, R. Bucalo, M. Rizzo, F. Agrusta, P. Landi, R. Sicari, E. Picano, A. Sutandar, B. B. Siswanto, I. Irmalita, G. Harimurti, S. Y. Hayashi, M. M. Nascimento, B. Lindholm, B. Lind, A. Seeberger, M. A. Pachaly, M. C. Riella, A. Bjallmark, L. A. Brodin, L. Poanta, M. Porojan, D. L. Dumitrascu, I. Ikonomidis, S. Tzortzis, J. Lekakis, D. T. Kremastinos, I. Paraskevaidis, I. Andreadou, M. Nikolaou, P. Katsibri, M. Anastasiou-Nana, A. M. Maceira Gonzalez, C. Ripoll, J. Cosin-Sales, B. Igual, J. Salazar, V. Belloch, J. Cosin-Aguilar, D. J. Pennell, M. Masaki, J. N. Pulido, T. Yuasa, S. Gillespie, B. Afessa, D. R. Brown, S. V. Mankad, J. K. Oh, A. L. Gurghean, A. M. Mihailescu, I. Tudor, C. Homentcovschi, M. Muraru, I. V. Bruckner, C. E. Correia, B. Rodrigues, D. Moreira, L. F. Santos, P. Gama, O. Dionisio, C. Cabral, O. Santos, T. Bombardini, S. Gherardi, G. Arpesella, S. Valente, I. Calamai, E. Pasanisi, S. Sansoni, P. Szymanski, P. Dobrowolski, M. Lipczynska, A. Klisiewicz, P. Hoffman, D. Stepowski, B. Kurtz, G. Grezis-Soulie, A. Savoure, F. Anselme, F. Bauer, J. Castillo, N. Herszkowicz, C. Ferreira, A. Goscinska, K. Mizia-Stec, W. Poborski, O. Azevedo, I. Quelhas, J. Guardado, M. Fernandes, C. S. Miranda, P. Gaspar, A. Lourenco, R. Medeiros, J. Almeida, S. L Bennani, V. Algalarrondo, S. Dinanian, J. Guiader, C. Juin, D. Adams, M. S. Slama, J. J. Onaindia, O. Quintana, S. Velasco, E. Astigarraga, A. Cacicedo, J. Gonzalez, I. Rodriguez, M. Sadaba, M. Eneriz, E. Laraudogoitia Zaldumbide, I. Nunez-Gil, M. Luaces, J. Zamorano, J. C. Garcia Rubira, D. Vivas, B. Ibanez, P. Marcos Alberca, C. Fernandez Golfin, J. Alonso, C. Macaya, J. Silva Marques, A. G. Almeida, V. Carvalho, C. Jorge, D. Silva, M. Gato Varela, S. Martins, D. Brito, M. G. Lopes, E. Tripodi, B. Miserrafiti, V. Montemurro, R. Scali, P. Tripodi, A. Winkler, A. Madej, I. Hausmanowa-Petrusewicz, M. Fijalkowski, A. Koprowski, M. Jaguszewski, R. Galaska, M. Taszner, A. Rynkiewicz, R. Citro, F. Rigo, G. Provenza, Q. Ciampi, M. M. Patella, A. D'andrea, O. Vriz, C. Astarita, E. Bossone, F. Heggemann, T. H. Walter, T. H. Kaelsch, T. Sueselbeck, T. H. Papavassiliu, M. Borggrefe, D. Haghi, T. Monk-Hansen, C. Have Dall, S. Bisgaard Christensen, M. Snoer, F. Gustafsson, H. Rasmusen, E. Prescott, G. Finocchiaro, B. Pinamonti, M. Merlo, G. Barbati, A. Di Lenarda, R. Bussani, G. Sinagra, T. Butz, C. N. Lang, A. Meissner, G. Plehn, H. Yeni, C. Langer, H. J. Trappe, X. Gu, X. Y. Gu, Y. H. He, Z. A. Li, J. C. Han, J. Chen, P. Gaudron, M. Niemann, S. Herrmann, K. Hu, B. Bijnens, H. Hillenbrand, M. Beer, G. Ertl, F. Weidemann, A. Mazzone, M. Mariani, I. Foffa, A. Vianello, S. Del Ry, S. Bevilacqua, M. G. Andreassi, M. Glauber, S. Berti, M. Grabowski, M. Postula, A. Dragulescu, G. Van Arsdell, O. Al-Radi, C. Caldarone, L. Mertens, K. J. Lee, R. P. Casula, H. Yadav, A. Cherian, A. D. Hughes, A. Vitarelli, S. D'orazio, B. L. Nguyen, G. Iorio, D. Battaglia, F. Caranci, V. Padella, L. Capotosto, L. Alessandroni, F. Barilla, C. Cardin, S. Hascoet, M. Saudron, G. Caudron, B. Arnaudis, P. Acar, M. M. Sun, X. H. Shu, C. Z. Pan, X. Y. Fang, D. H. Kong, F. Fang, Q. Zhang, Y. S. Chan, J. M. Xie, W. K. Yip, Y. Y. Lam, J. E. Sanderson, C. M. Yu, M. Rosca, K. O' Connor, G. Romano, J. Magne, A. Calin, D. Muraru, L. Pierard, P. Lancellotti, A. Roushdy, I. Elfiky, G. El Shahid, A. Elfiky, M. El Sayed, K. Wierzbowska-Drabik, L. Chrzanowski, A. Kapusta, E. Plonska-Goscinak, M. Krzeminska-Pakula, M. Kurpesa, T. Rechcinski, E. Trzos, J. D. Kasprzak, M. K. Ersboll, N. Valeur, U. M. Mogensen, M. Andersen, C. Hassager, P. Sogaard, L. V. Kober, M. Kloeckner, D. Hayat, C. Dussault, N. Lellouche, N. Elbaz, A. Demopoulos, G. Hatzigeorgiou, E. Leontiades, A. Motsi, G. Karatasakis, G. Athanassopoulos, P. Zycinski, J. Kasprzak, M. C. Vazquez Alvarez, C. Medrano Lopez, M. Camino Lopez, S. Granja, J. L. Zunzunegui Martinez, E. Maroto Alvaro, W.-C. Tsai, J.-Y. Chen, Y.-W. Liu, C.-C. Lin, L.-M. Tsai, D. C. Gomes, S. Robalo Martins, M. R. Gois, S. Ribeiro, A. Nunes Diogo, P. Sengupta, G. Di Bella, G. Caracciolo, S. Lentini, E. Kinova, N. Zlatareva, A. Goudev, N. Papagiannis, M. Mpouki, A. Papagianni, M. Vorria, G. Mpenetos, D. Lytra, E. Papadopoulou, P. Sgourakis, J. Malakos, J. Kyriazis, V. Kodali, R. Toole, A. S. Gopal, J. Celutkiene, A. Rudys, V. Grabauskiene, S. Glaveckaite, E. Sadauskiene, Z. Lileikiene, N. Bickauskaite, E. Ciburiene, V. Skorniakov, A. Laucevicius, C. H. Attenhofer Jost, M. Pfyffer, R. Lindquist, J. L. F. Santos, O. R. C. Coelho, C. M. Mady, M. H. P. Picard, V. M. C. Salemi, L. Funk, M. W. Prull, J.-Y. Shih, Y.-Y. Huang, K. O'connor, M. Moonen, L. A. Pierard, D. C. Cozma, C. Mornos, A. Ionac, L. Petrescu, D. Dragulescu, R. Dan, I. Popescu, S. I. Dragulescu, T. G. Von Lueder, A. Hodt, G. F. Gjerdalen, T. E. Andersen, E. E. Solberg, K. Steine, T. Van Mieghem, M. Rostek, W. Pikto-Pietkiewicz, M. Dluzniewski, A. Antoniewicz, S. Poletajew, A. Borowka, T. Pasierski, S. K. Malyutina, M. Ryabikov, J. Ragino, A. Ryabikov, S. Sitia, L. Tomasoni, F. Atzeni, L. Gianturco, P. Sarzi-Puttini, V. De Gennaro Colonna, M. Turiel, F. R. Gutierrez, G. Lefhtheriotis, R. T. Hurst, M. R. Nelson, F. Mookadam, V. Thota, U. Emani, M. Al Harthi, J. Stepanek, S. Cha, S. J. Lester, E. M. M. Ho, L. Hemeryck, M. Hall, K. Scott, K. Bennett, A. Mahmud, C. Daly, G. King, R. T. Murphy, A. S. Brown, A. J. Teske, J. D'Hooge, P. Claus, F. Rademakers, L. Santos, N. Cortez-Dias, S. Goncalves, M. Almeida Ribeiro, A. Bordalo E Sa, C. Magnino, P. Marcos-Alberca, A. Milan, C. Almeria, V. Caniadas, J. L. Rodrigo, L. Perez De Isla, J. L. Zamorano, U. Gustafsson, M. Larsson, P. Lindqvist, L. Brodin, A. Waldenstrom, B. Roosens, S. Hernot, S. Droogmans, G. Van Camp, T. Lahoutte, B. Cosyns, C. M. Rao, D. Aguglia, G. Casciola, C. Imbesi, A. Marvelli, M. Sgro, D. Benedetto, R. Tripepi, C. Zoccali, F. A. Benedetto, L. P. Badano, M. Cardillo, L. Del Mestre, P. Gianfagna, A. Proclemer, H. D. Tschernich, B. Mora, E. Base, U. Weber, J. Dumfarth, C. Mukherjee, H. S. Skaltsiotis, A. K. Kaladaridis, D. B. Bramos, G. K. Kottis, A. A. Antoniou, I. A. Agrios, D. T. Takos, N. V. Vasiladiotis, K. P. Pamboucas, S. T. T. Toumanidis, A. Shim, P. Lipec, B. Michalski, B. Wozniakowski, L. Stefanczyk, A. Rotkiewicz, M. Cameli, M. Lisi, M. Padeletti, E. Bigio, S. Bernazzali, C. Tsoulpas, M. Maccherini, M. Henein, S. Mondillo, I. Garcia Lunar, S. Mingo Santos, V. Monivas Palomero, C. Mitroi, P. Beltran Correas, L. Ruiz Bautista, A. Muniz Lozano, M. Gonzalez Gonzalez, B. Stegemann, K. Willson, R. Zeppellini, A. Iavernaro, M. Zadro, M. Carasi, R. De Domenico, T. Rigo, E. Artuso, G. Erente, A. Ramondo, T. T. Le, F. Q. Huang, Y. Gu, and R. S. Tan
- Subjects
Cardiac function curve ,medicine.medical_specialty ,medicine.anatomical_structure ,business.industry ,Ventricle ,Internal medicine ,medicine ,Cardiology ,Radiology, Nuclear Medicine and imaging ,General Medicine ,Cardiology and Cardiovascular Medicine ,Rotation ,business - Published
- 2010
- Full Text
- View/download PDF
13. 0559 Soft Cervical Collar in Obstructive Sleep Apnea, A Pilot Study
- Author
-
P. Bordier, A. Lataste, and S. Orazio
- Subjects
Obstructive sleep apnea ,medicine.anatomical_structure ,business.industry ,Physiology (medical) ,Pharynx ,medicine ,Dentistry ,Cervical collar ,Neurology (clinical) ,business ,medicine.disease - Published
- 2018
- Full Text
- View/download PDF
14. Évaluation de l’impact des comorbidités sur la survie nette des patients Girondins atteints de myélomes multiples/Plasmocytomes en population générale (2002–2013) : exemple d’utilisation des modèles flexibles du taux de mortalité en excès
- Author
-
Alain Monnereau, Michel Grzebyk, S. Orazio, Laurent Remontet, and Zoé Uhry
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health - Abstract
Introduction Le myelome multiple (MM) et le plasmocytome (P) sont des hemopathies lymphoides a cellules B matures diagnostiquees chez des patients plutot âges (mediane d’âge au diagnostic de 75 ans chez les femmes et 72 ans chez les hommes) dont le pronostic reste severe malgre les progres recents de leur prise en charge. La complexite croissante de l’arsenal therapeutique rend necessaire l’utilisation de modeles de risque les plus precis pour definir des groupes pronostiques homogenes et proposer ainsi des plans de traitement ajustes au pronostic. Or, les deux scores pronostiques en usage dans les cas de MM/P (ISS et Durie-Salmon) n’integrent pas d’information sur les comorbidites alors que la relation entre une comorbidite severe et un pronostic defavorable est pourtant etablie. Cette etude a donc pour objectif principal de determiner l’impact des comorbidites sur la survie « nette » a cinq ans des patients Girondins diagnostiques entre 2002–2013 avec un MM/P en utilisant une methode de modelisation statistique adequate aux etudes en population : un modele flexible du taux de mortalite en exces. Methodes La population d’etude est constituee par tous les cas de MM/P diagnostiques chez des patients residant en Gironde entre le 01/01/2002 et le 31/12/2013. Les variables recueillies sont le sexe, la date de diagnostic, le code morphologique, le statut vital, l’ACE-27 (Index de comorbidite) et le stade de Durie-Salmon. Les patients ont ete suivis jusqu’au 01/01/2016. Les estimations ponctuelles de survie « nette » sont calculees avec la methode de pohar-perme. Le modele flexible utilise est celui decrit par L. Remontet et al. Nous utilisons la strategie de modelisation des effets complexes proposee par W. Wynant et M. Abrahamowicz. Resultats Au total, 1176 patients sont inclus dans l’etude avec moins de 2,5 % de perdus de vue a la date de point. La mediane d’âge des patients est 73 ans. Les patients sans comorbidite ou avec une comorbidite peu severe representent 68 % des cas. Le modele final retient un effet non-proportionnel et non lineaire de l’âge, un effet proportionnel de l’ACE-27. Il n’y pas d’interaction entre l’âge et l’ACE-27. Le risque de mortalite en exces estime est respectivement de 1,5 [1,2 ; 1,9] et 1,8 [1,4 ; 2,3] pour les comorbidites moderees et severes en prenant comme reference les patients sans comorbidite ou avec une comorbidite legere au diagnostic. Conclusion Les comorbidites ont un impact defavorable sur la survie nette a cinq ans des patients atteints d’un MM/P suivant un gradient qui augmente avec leur severite. Bien que l’incidence des MM/P augmente avec l’âge, les comorbidites impactent la survie nette de facon identique que ce soit chez les plus jeunes ou les plus âges. Cependant des investigations complementaires sont necessaires afin d’ajuster les modeles sur la toxicite des traitements dispenses (facteur de confusion potentiel).
- Published
- 2017
- Full Text
- View/download PDF
15. Moderated Posters session V: How to assess right ventricular function? * Saturday 11 December 2010, 10:00-11:00
- Author
-
K. G. Adamyan, L. R. Tumasyan, H. B. Van Der Zwaan, K. Y. E. Leung, O. I. I. Soliman, G. Van Burken, J. G. Bosch, J. S. Mcghie, J. W. Roos-Hesselink, M. L. Geleijnse, F. J. Meijboom, W. A. Helbing, L. Fusini, G. Tamborini, P. Gripari, F. Maffessanti, V. Mazzanti, M. Muratori, L. Salvi, M. Zanobini, F. Alamanni, M. Pepi, C. Hammerstingl, D. Momcilovic, S. Pabst, R. Schueler, D. Skowasch, I. Simkova, M. Kaldararova, A. Vitarelli, Y. Conde, S. D'orazio, G. Continanza, L. Capotosto, M. Vitarelli, V. De Cicco, M. De Maio, C. Terzano, F. Salsano, N. Mansencal, N. Abbou, R. El Mahmoud, R. Pilliere, O. Dubourg, M. Kukucka, A. Stepanenko, E. Potapov, A. Mladenow, H. Kuppe, and H. Habazettl
- Subjects
medicine.medical_specialty ,Ventricular function ,business.industry ,Physical therapy ,medicine ,Radiology, Nuclear Medicine and imaging ,General Medicine ,Session (computer science) ,Cardiology and Cardiovascular Medicine ,business - Published
- 2010
- Full Text
- View/download PDF
16. Gestion des données manquantes (DM) et modélisation de la survie nette : illustration de l’impact du choix de la méthode en épidémiologie des cancers
- Author
-
Alain Monnereau, S. Orazio, and S. Le Guyader-Peyrou
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health - Abstract
Introduction En restituant l’impact propre de la maladie sur la mortalite du collectif de patients etudies, la survie nette est devenue une methode d’analyse incontournable en epidemiologie des cancers, surtout lorsque l’on souhaite realiser des comparaisons de survie dans l’espace ou le temps. Son estimation parametrique repose sur la modelisation du taux de mortalite en exces. Malgre un controle serre de la qualite des donnees, la quantite de donnees manquantes peut atteindre parfois une proportion non negligeable dans les etudes retrospective en population generale. Ne pas prendre en compte le manque de completude des informations peut conduire a une inference erronee ou a des estimations biaisees. Nous proposons ici d’illustrer l’utilisation de differentes methodologies de gestion des DM et d’evaluer l’influence de ce choix sur l’ajustement de modeles du taux de mortalite en exces. Methode Nous comparons trois methodes de gestion des DM (complete case analysis [CCA], missing data indicator [MDI] et multivariate imputation by chained equations [MICE]) sur l’analyse multivariee du taux de mortalite en exces (modele d’Esteve). Pour chacune des trois methodes de gestion des DM nous appliquons la meme strategie de modelisation : – selection des covariables associees en univarie aux taux de mortalite en exces (p – strategie de modelisation pas a pas descendante ; – verification de l’adequation des modeles (ponts Brownians). Concernant l’algorithme MICE son utilisation necessite de verifier au prealable que les donnees soient manquantes au hasard conditionnellement au statut vital (decedes/censures). Nous appliquons egalement les lois de Rubin afin de synthetiser les estimations obtenues par MICE. Les modeles obtenus selon les differentes methodes de gestion des DM sont compares en fonction : des covariables selectionnees, la difference absolue moyenne entre les parametres, la variance des estimateurs, l’adequation des modeles. Nous appliquons cette methodologie sur les donnees de l’etude IsoLymph, une etude de cohorte retrospective exhaustive d’environ 2000 patients francais atteints d’un lymphome folliculaire ou diffus a grandes cellules B (entre 2002–2008). Elle cherche a identifier les determinants associes a la survie de ces patients et en particulier l’impact des inegalites sociales. Resultats L’analyse a porte sur les 1102 cas de lymphome diffus B. Sur la quinzaine de variables etudiees cinq possedent des DM (etat general, comorbidite, stade au diagnostic, EDI, solitude). La gestion des DM par MDI et MICE a permis de travailler sur l’ensemble des cas, contrairement au CCA qui supprime de l’analyse 221 patients (20 %), ce qui se traduit par une augmentation de la variance des estimateurs. Les estimations des parametres du modele final different aussi selon les methodes utilisees avec une difference absolue moyenne de 8 % entre MICE versus CCA et de 2 % entre MICE versus MDI. Enfin, l’utilisation du MDI a rendu le modele non proportionnel au cours du temps sur la modalite missing de la variable solitude. Conclusion Des etudes par simulations Monte Carlo, ont montre que dans le cas d’une typologie de DM de type missing at random et dans un contexte de modelisation parametrique du taux de mortalite en exces, le MICE fourni les parametres les moins biaises et les plus precis, ceci est le cas dans notre etude. Cette technique nous permet egalement d’obtenir un modele plus adequat que le MDI.
- Published
- 2016
- Full Text
- View/download PDF
17. Mitral valve replacement: Randomized trial of St. Jude and medtronic-hall prostheses
- Author
-
A C, Fiore, K S, Naunheim, S, D'Orazio, G C, Kaiser, L R, McBride, D G, Pennington, P S, Peigh, V L, Willman, A J, Labovitz, and H B, Barner
- Subjects
Adult ,Aged, 80 and over ,Male ,Pulmonary and Respiratory Medicine ,Adolescent ,Mitral Valve Insufficiency ,Middle Aged ,Prosthesis Design ,Survival Analysis ,Postoperative Complications ,Echocardiography ,Cause of Death ,Heart Valve Prosthesis ,Humans ,Mitral Valve ,Female ,Surgery ,Prospective Studies ,Child ,Cardiology and Cardiovascular Medicine ,Aged - Abstract
To better define the merits of the bileaflet and tilting-disc valves, we prospectively randomized 102 patients (mean age, 57 years; range, 11 to 85 years) to receive either the St. Jude (n = 55) or the Medtronic-Hall (n = 47) mitral valve prosthesis between September 1986 and May 1991. The two groups were not different with respect to preoperative New York Heart Association class, incidence of mitral stenosis and insufficiency, angina score, extent of coronary artery disease, ventricular function, completeness of revascularization, or cross-clamp or bypass time. The hospital mortality (14.5% versus 10.6%, St. Jude versus Medtronic-Hall) and late mortality (7.3% versus 2.1%) were not significantly different. Follow-up was complete in 84 of 89 hospital survivors (94%) with a mean of 26 months (range, 1 to 60 months). The linearized rates of valve-related events and the 3-year actuarial survival demonstrated no significant differences between both cohorts. Comparison of the clinical outcome and echocardiographic parameters obtained at the time of follow-up demonstrated no significant differences between the two prostheses. These data indicate that the Medtronic-Hall and St. Jude mitral prostheses are similar with respect to their rates of valve-related complications and hemodynamic profiles. This study suggests that there is no difference between the St. Jude and Medtronic-Hall prostheses with regard to early clinical performance or hemodynamic results and therefore does not support the preferential selection of either prosthesis.
- Published
- 1992
- Full Text
- View/download PDF
18. Seasonal and geographic variation of atrial tachyarrhythmias in pacemaker recipients
- Author
-
M. Gulizia, L. Padeletti, R. Ricci, A. Proclemer, S. Orazio, P. Pieragnoli, T. Marotta, T. DeSabto, M. Santini, BORIANI, GIUSEPPE, M.Gulizia, L.Padeletti, R.Ricci, G.Boriani, A.Proclemer, S.Orazio, P.Pieragnoli, T.Marotta, T.DeSabto, and M.Santini
- Published
- 2004
19. LP-based heuristics for the capacitated lot-sizing problem: the interaction of model formulation and solution algorithm
- Author
-
Arianna Alfieri, Paolo Brandimarte, and S. D'Orazio
- Subjects
Mathematical optimization ,Strategy and Management ,Rounding ,Computation ,Management Science and Operations Research ,Industrial and Manufacturing Engineering ,symbols.namesake ,Lagrangian relaxation ,Shortest path problem ,symbols ,Point (geometry) ,Sensitivity (control systems) ,Heuristics ,Algorithm ,Interior point method ,Mathematics - Abstract
We consider here the application of trivial LP-based rounding heuristics to the capacitated lot-sizing problem (CLSP). The motivation behind the use of LP-based heuristics is that their extension to cope with complicating features (to be expected, for example, when dealing with a master production scheduling problem within a MRP system) is generally easier than with alternative approaches such as lagrangian relaxation. It is well known that strong model formulations, like the Plant Location Formulation (PLF) or the Shortest Path Formulation (SPF), are needed to obtain good results when working on a CLSP. Still, from a practical point of view, a few questions deserve investigation. First, the relative performance of PLF and SPF should be assessed. Second, given the increased size of the more complicated formulations, the possible benefits of using interior point methods must be considered. Third, the sensitivity of the computation times with respect to the characteristics of problem instances should be eva...
- Published
- 2002
20. Facteurs associés à la survenue d’un second cancer après un lymphome de Hodgkin, France
- Author
-
Jérémie Jégu, C. Lacueille, S. Orazio, and Alain Monnereau
- Subjects
Epidemiology ,Public Health, Environmental and Occupational Health - Abstract
Introduction Nous proposons d’estimer le risque de survenue d’un second cancer apres un diagnostic de Lymphome de Hodgkin (LH). Methodes La population d’etude correspond a tous les cas incidents de LH enregistres par 10 registres de cancer francais entre 1989 et 2004. Les patients ont ete suivis jusqu’au 31/12/2007. Les indicateurs utilises comportaient le rapport d’incidence standardise (RIS) et l’exces de risque absolu (ERA) de second cancer. L’analyse des facteurs associes aux RIS et ERA a ete realisee a l’aide de regressions de Poisson. Resultats Le RIS diminuait en fonction de la periode du diagnostic (RIS = 1,9 [1,4 ; 2,5] pour 1989–1994 et 1,4 [0,9 ; 2,1] pour 2000–2004). A l’inverse, celui-ci augmentait en fonction de la duree du suivi (RIS = 1,4 [1,0 ; 1,9] pour un suivi de 2 mois a 5 ans et 2,2 [1,6 ; 3,1] pour un suivi de plus de 9 ans). Les analyses multivariees ont confirme ces tendances sans toutefois atteindre la significativite statistique. Discussion Nous avons observe un risque eleve de second cancer apres un premier LH. Ce risque etait plus eleve pour les patients ayant un suivi superieur a neuf ans ce qui pourrait s’expliquer par les effets secondaires a long terme des traitements du premier cancer. La diminution du risque observee pour la periode la plus recente apres 2000 est contemporaine d’une modification des standards de traitement mais ces resultats doivent etre confirmes par un suivi a plus long terme.
- Published
- 2014
- Full Text
- View/download PDF
21. [Serum levels of beta-methyldigoxin and contractile efficiency of the myocardium evaluated with systolic polygraphy and determination of cardiac output]
- Author
-
G, Pelosi, G, Bracchi, S, Orazio, and A, Cereda
- Subjects
Adult ,Male ,Digoxin ,Heart Diseases ,Systole ,Hemodynamics ,Phonocardiography ,Stroke Volume ,Middle Aged ,Cardiovascular System ,Myocardial Contraction ,Electrocardiography ,Carotid Arteries ,Medigoxin ,Humans ,Cardiac Output ,Pulse ,Aged - Abstract
0.3 mg/day betamethyldigoxin was given per os in three daily administrations to 8 healthy subjects, and 8 compensated and 8 decompensated heart patients. Prior to the treatment, and 6 hr after the last administration, blood digoxin values were determined radio-immunologically, together with cardiac output, systolic stroke volume, cardiac index (dilution of indocyanine green), and systolic time intervals, by simultaneous recording of the ECG, carotid pulse, and the phonocardiogram. No significant change in output, stroke volume and cardiac index was noted in the healthy subjects, whereas these parameters were distinctly improved in the decompensated patients. Changes in the systolic intervals after treatment were significant in all cases though there was no significant correlation with the blood digoxin levels reached. In particular, the healthy and compensated subjects displayed a reduction in the corrected electromechanical systole (delta Q-S2), the corrected pre-ejection period (delta PEP), the corrected left ventricular ejection time (delta LVET), and their ratio (PEP/LVET), whereas in the decompensated patients the picture differed to the extent that the LVET increased owing to an augment-systolic stroke volume, the other parameters being reduced. In the healthy subjects, the polygraphic data were normal prior to the treatment, while in the compensated patients delta PEP and the PEP/LVET ratio were enhanced, and the delta LVET was less than in the normal subjects. It is felt that recording of the systolic intervals may be regarded as a sound method, owing to its simplicity and its ability to demonstrate latent cardiac failure before haemodynamic changes appear. Simultaneous determination of serum digoxin and the polygraphic data, therefore, opens the way to the commencement of appropriate, safe and timely management of as yet non-decompensated heart patients.
- Published
- 1981
22. [Value of simultaneous determination of polygraphic indices and of blood digoxin for beginning and continuing digitalis therapy]
- Author
-
G, Pelosi, S, Orazio, P, Motta, and A, Cereda
- Subjects
Adult ,Heart Failure ,Male ,Digoxin ,Heart Function Tests ,Humans ,Heart ,Middle Aged ,Aged - Published
- 1977
23. [Metabolic compensation and chronic obliterating arteriopathy in diabetes mellitus]
- Author
-
G, Conconi, S, Orazio, M, Managlia, and E, Scioli
- Subjects
Cholesterol ,Arteriosclerosis ,Diabetes Mellitus ,Humans ,Intermittent Claudication ,Lipoproteins, HDL ,Diabetic Angiopathies ,Triglycerides - Abstract
The following parameters were determined in 20 diabetics with chronic obliterating arteriopathy of the lower extremities: C-HDL, apo-A1, apo-B, triglyceridaemia, the glycaemic profile and HbA1c oscillometry, photoplethysmogram and claudication distance on a treadmill. Examination of the results obtained did not show any variation in the lipoproteic picture and only an improvement, in some subjects, in claudication distance. It is therefore hypothesised that in diabetic C-HDL and apo-A1 are not predictive of atherosclerotic risk although it cannot be excluded that changes in such constants may represent a synergetic factor in determining arteriosclerosis.
- Published
- 1981
24. Design Principles of the Italian Round Robin Test on Reverberation Rooms
- Author
-
Scrosati C., Annesi D., Barbaresi L., Baruffa R., D’Angelo F., De Napoli G., Depalma M., Di Bella A., Di Filippo S., D’Orazio D., Garai M., Granzotto N., Lori V., Martellotta F., Moschetto A., Pompoli F., Prato A., Nataletti P., Scamoni F., Schiavi A., Serpilli F., Ochmann M., and Scrosati C., Annesi D., Barbaresi L., Baruffa R., D’Angelo F., De Napoli G., Depalma M., Di Bella A., Di Filippo S., D’Orazio D., Garai M., Granzotto N., Lori V., Martellotta F., Moschetto A., Pompoli F., Prato A., Nataletti P., Scamoni F., Schiavi A., Serpilli F.
- Subjects
round robin test ,Sound absorption, Reverberation room, Round Robin Test, ISO 354 ,ISO 354 ,Reverberation room ,Round Robin Test ,Sound absorption ,PE8_3 ,Sound Absorption ,reverberation room ,NO - Abstract
Proceedings of the ICA 2019 and EAA Euroregio : 23rd International Congress on Acoustics, integrating 4th EAA Euroregio 2019 : 9-13 September 2019, Aachen, Germany / proceedings editor: Martin Ochmann, Michael Vorländer, Janina Fels 23rd International Congress on Acoustics, integrating 4th EAA Euroregio 2019, ICA 2019, Aachen, Germany, 9 Sep 2019 - 13 Sep 2019; Aachen (2019)., Published by Aachen
- Published
- 2019
- Full Text
- View/download PDF
25. Dysregulation of the Arachidonic Acid Pathway in Cystic Fibrosis: Implications for Chronic Inflammation and Disease Progression.
- Author
-
D'Orazio S and Mattoscio D
- Abstract
Cystic fibrosis (CF) is the most common fatal genetic disease among Caucasian people, with over 2000 mutations in the CFTR gene. Although highly effective modulators have been developed to rescue the mutant CFTR protein, unresolved inflammation and persistent infections still threaten the lives of patients. While the central role of arachidonic acid (AA) and its metabolites in the inflammatory response is widely recognized, less is known about their impact on immunomodulation and metabolic implications in CF. To this end, here we provided a comprehensive analysis of the AA metabolism in CF. In this context, CFTR dysfunction appeared to complexly disrupt normal lipid processing, worsening the chronic airway inflammation, and compromising the immune responses to bacterial infections. As such, potential strategies targeting AA and its inflammatory mediators are being investigated as a promising approach to balance the inflammatory response while mitigating disease progression. Thus, a deeper understanding of the AA pathway dysfunction in CF may open innovative avenues for designing more effective therapeutic interventions.
- Published
- 2024
- Full Text
- View/download PDF
26. Factors influencing access to specialised haematology units during acute myeloblastic leukaemia patient care: A population-based study in France.
- Author
-
Atsou KM, Rachet B, Cornet E, Chretien ML, Rossi C, Remontet L, Roche L, Giorgi R, Gauthier S, Girard S, Böckle J, Wasse SK, Rachou H, Bouzid L, Poncet JM, Orazio S, Monnereau A, Troussard X, Mounier M, and Maynadie M
- Subjects
- Humans, Aged, 80 and over, Prognosis, Cytogenetic Analysis, Patient Care, Leukemia, Myeloid, Acute diagnosis, Leukemia, Myeloid, Acute epidemiology, Leukemia, Myeloid, Acute therapy, Hematology
- Abstract
Background: The excess mortality observed in Acute Myeloblastic Leukaemia (AML) patients, partly attributed to unequal access to curative treatments, could be linked to care pathways., Methods: We included 1039 AML incident cases diagnosed between 2012-2016 from the 3 French blood cancer registries (3,625,400 inhabitants). We describe patients according to age, the medical entry unit and access to the specialised haematology unit (SHU) during follow-up. Multivariate logistic regression model was done to determine the association between covariables and access to SHU. A total of 713 patients (69%) had access to SHU during care., Results: The most common care pathway concerned referral from the general practitioner to SHU, n = 459(44%). The univariate analysis observed a downward trend for the most deprived patients. Patients who consulted in SHU were younger (66 years vs. 83, p < 0.001), and 92% had access to cytogenetic analysis (vs. 54%, p < 0.001). They also had less poor prognosis AML-subtypes (AML-MRC, t-AML/MDS and AML-NOS) (38% vs. 69%); 77% with de novo AML (vs. 67%, p < 0.003)], more favourable cytogenetic prognostic status (23% vs. 6%, p < 0.001), less comorbidities (no comorbidity = 55% vs. 34%, p < 0.001) and treatments proposed were curative 68% (vs. 5.3%, p < 0.001). Factors limiting access to SHU were age over 80 years (OR, 0.14; 95% CI, 0.04-0.38), severe comorbidities (OR, 0.39; 95% CI, 0.21-0.69), emergency unit referral (OR, 0.28; 95% CI, 0.18-0.44) and non-SHU referral (OR, 0.12; 95% CI, 0.07-0.18). Consultation in an academic hospital increased access to SHU by 8.87 times (95% CI, 5.64-14.2)., Conclusion: The high proportion of access to cytogenetic testing and curative treatment among patients admitted to SHU, and the importance of early treatment in AML underlines the importance of access to SHU for both diagnosis and treatment., (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
27. [Process to insulin for type 2 diabetes mellitus therapy].
- Author
-
Cosmi F, D'Orazio S, Mariottoni B, Tarquini B, and Cosmi D
- Subjects
- Aged, Blood Glucose, Humans, Hypoglycemic Agents adverse effects, Retrospective Studies, Diabetes Mellitus, Type 2 drug therapy, Insulin
- Abstract
In type 1 diabetes mellitus and in symptomatic and critical hyperglycemic states, insulin is a lifesaving drug; however, its value in long-term type 2 diabetes therapy, which represents more than 90% of diabetes, has not been assessed. This happens despite the fact that, in randomized studies on type 2 diabetes, insulin is used in two-thirds of cases when intensive hypoglycemic treatment is needed and in half of the patients when treatment is the standard one. This is a major issue from a clinical, economic and social-health organization point of view as insulin therapy is expensive and needs a complex organization. Observational and retrospective studies from the scientific literature show that in this type of diabetes insulin treatment is associated with increased cardiovascular and all-cause mortality. It is not clear whether this is due to a greater severity of the clinical picture, to the therapeutic target of blood glucose that may induce hypoglycemia, or to the intrinsic pharmacological activity of the drug that beyond reducing hyperglycemia can cause hypoglycemia, water retention, weight gain and hyperinsulinemia with proatherogenic effects. In particular, in patients with heart failure at high cardiovascular risk or with high insulin resistance, these clues are supported by meaningful data. Although there is no definitive evidence (the so-called "smoking gun") from randomized controlled trials, the high degree of suspicion induces the preferential choice of other drugs such as sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and metformin beyond avoiding glycemic targets that induce hypoglycemia, especially in frail, elderly patients, or patients with cardiovascular diseases. These drugs, for their proven efficacy and the easy use within an outpatient setting (that favors their prescription and improves the inertia of the doctor and the adherence of patients), could help a more effective treatment of patients, both for quality and life expectancy beyond mere glycemic control.
- Published
- 2022
- Full Text
- View/download PDF
28. Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
- Author
-
Canet J, Cony-Makhoul P, Orazio S, Cornet E, Troussard X, Maynadié M, Étienne G, and Monnereau A
- Subjects
- Adult, Aged, Aniline Compounds therapeutic use, Dasatinib therapeutic use, Female, France, Humans, Imidazoles therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive mortality, Male, Middle Aged, Multivariate Analysis, Nitriles therapeutic use, Pyridazines therapeutic use, Pyrimidines therapeutic use, Quinolines therapeutic use, Registries, Remission Induction, Treatment Outcome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Protein Kinase Inhibitors therapeutic use
- Abstract
Introduction: Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new-generation TKI (NG-TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population?, Materials and Methods: Patients were identified from the three French hematological malignancies population-based registries. All CML patients (ICD-O-3: 9875/3) diagnosed between 2006 and 2016 and resided in registries areas were included. The TKI generation effect on achievement of MMR in first-line therapy was assessed through a multivariate competitive risk analysis. An alluvial plot described the pathways leading to death., Results: In total, 507 CML patients received TKI in first-line treatment, 22% were enrolled in a clinical trial. After adjustment, NG-TKI patients were significantly more likely to achieve MMR during first-line therapy than IM patients (HR: 1.88 CI
95% [1.35-2.61]). At the end of follow-up, 212 patients were still in first-line therapy (46 of them died), 203 switched to second-line (43 subsequently died), 26 were on TFR from first-line (4 subsequently died), and 20 stopped their treatment (16 subsequently died)., Discussion: In this comprehensive real-life setting, the results were consistent with clinical trials. The results are not sufficient to conclude that a NG-TKI treatment is superior with regard to these patients, despite indications regarding differences between the TKI generation effect on survival and tolerance., (© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)- Published
- 2021
- Full Text
- View/download PDF
29. Passive environmental residential exposure to agricultural pesticides and hematological malignancies in the general population: a systematic review.
- Author
-
Roingeard C, Monnereau A, Goujon S, Orazio S, Bouvier G, and Vacquier B
- Subjects
- Agriculture, Child, Cohort Studies, Environmental Exposure analysis, Humans, Hematologic Neoplasms chemically induced, Hematologic Neoplasms epidemiology, Pesticides adverse effects, Pesticides analysis
- Abstract
Incidence rates of hematological malignancies have been constantly increasing over the past 40 years. In parallel, an expanding use of agricultural pesticides has been observed. Only a limited number of studies investigated the link between hematological malignancies risk and passive environmental residential exposure to agricultural pesticides in the general population. The purpose of our review was to summarize the current state of knowledge on that question. A systematic literature search was conducted using PubMed and Scopus databases. We built a scoring scale to appraise relevance of each selected articles. We included 23 publications: 13 ecological studies, 9 case-control studies and a cohort study. Positive associations were reported between hematological malignancies and individual pesticides, pesticide groups, all pesticides without distinction, or some crop types. Relevance score was highly various across studies regardless of their design. Children studies were the majority and had overall higher relevance scores. The effect of passive environmental residential exposure to agricultural pesticides on hematological malignancies risk is suggested by the literature. The main limitation of the literature available is the high heterogeneity across studies, especially in terms of exposure assessment approach. Further studies with high methodological relevance should be conducted., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
30. Palliative care referral in cancer patients with regard to initial cancer prognosis: a population-based study.
- Author
-
Frasca M, Orazio S, Amadeo B, Sabathe C, Berteaud E, Galvin A, Burucoa B, Coureau G, Baldi I, Monnereau A, and Mathoulin-Pelissier S
- Subjects
- France, Humans, Referral and Consultation, Retrospective Studies, Lung Neoplasms, Palliative Care
- Abstract
Objectives: More than half of cancer patients require palliative care; however, inequality in access and late referral in the illness trajectory are major issues. This study assessed the cumulative incidence of first hospital-based palliative care (HPC) referral, as well as the influence of patient-, tumor-, and care-related factors., Study Design: This is a retrospective population-based study., Methods: The study included patients from the 2014 population-based cancer registry of Gironde, France. International Classification of Diseases, Tenth Revision, coding for palliative care identified HPC referrals from 2014 to 2018. The study included 8424 patients. Analyses considered the competing risk of death and were stratified by initial cancer prognosis (favorable vs unfavorable [if metastatic or progressive cancer])., Results: The 4-year incidence of HPC was 16.7% (95% confidence interval, 16.6-16.8). Lung cancer led to more referrals, whereas breast, colorectal, and prostatic locations were associated to less frequent HPC compared with other solid tumors. Favorable prognosis central nervous system tumors and unfavorable prognosis hematological malignancies also showed less HPC. The incidence of HPC was higher in tertiary centers, particularly for older patients. In the favorable prognosis subgroup, older and non-deprived patients received more HPC. In the unfavorable prognosis subgroup, the incidence of HPC was lower in patients who lived in rural areas than those who lived in urban areas., Conclusions: One-sixth of cancer patients require HPC. Some factors influencing referral depend on the initial cancer prognosis. Our findings support actions to improve accessibility, especially for deprived patients, people living in rural areas, those with hematological malignancies, and those treated outside tertiary centers. In addition, consideration of age as factor of HPC may allow for improved design of the referral system., (Copyright © 2021 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
31. Incidence, prognostic impact and clinical outcomes of renal impairment in patients with multiple myeloma: a population-based registry.
- Author
-
Courant M, Orazio S, Monnereau A, Preterre J, Combe C, and Rigothier C
- Subjects
- Aged, Aged, 80 and over, Female, France epidemiology, Humans, Incidence, Male, Middle Aged, Prognosis, Renal Insufficiency etiology, Renal Insufficiency pathology, Retrospective Studies, Survival Rate, Multiple Myeloma complications, Registries statistics & numerical data, Renal Insufficiency epidemiology, Renal Insufficiency mortality
- Abstract
Background: Renal impairment (RI), a severe complication in multiple myeloma (MM), is considered as a poor prognostic factor. Patient survival has increased with the use of novel drugs and autologous stem-cell transplantation (ASCT). However, specific evolution of the incidence of RI in MM and its impact on prognosis remain unclear., Methods: Using a population-based registry of 1038 newly diagnosed MM in Gironde, France, we evaluated the incidence trends of RI in MM patients and assessed net survival according to factors of interest using Pohar-Perme indicator and excess mortality rate regression. We also reviewed 114 cases of MM with RI to describe their clinical outcomes., Results: In our population-based study, 24.6% of MM patients presented with RI (12.9% required haemodialysis). Median survival time was 21 months in patients with RI versus not reached at 3 years for other patients (P < 0.01). Age >73 years, RI, comorbidities and non-use of drugs or ASCT were associated with excess mortality risk. The effect of RI on excess mortality rates was maximum in the first 6 months after diagnosis. In the observational study, median follow-up time was 22.5 months; factors associated with renal response were haematologic response [odds ratio (OR) 6.81; P < 0.01] and previous chronic kidney disease (OR 0.26; P = 0.04). Factors associated with 1-year overall survival were haematological [hazard ratio (HR) 0.13; P < 0.01] and renal response (HR 0.27; P = 0.03)., Conclusions: RI represents an independent negative prognostic factor in MM in the first 6 months after diagnosis. Renal recovery and haematologic response are the strongest markers associated with patient survival., (© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
32. Soft cervical collar in obstructive sleep apnoea: a pilot study.
- Author
-
Bordier P, Lataste A, Orazio S, Papin J, Robert F, and Bourenane G
- Abstract
In severe obstructive sleep apnoea, a soft cervical collar was well tolerated at night in 10 patients with no changes in polygraphy results. With the same design, a randomised controlled trial would need 246 inclusions for conclusive results. https://bit.ly/2KiU3j1., Competing Interests: Conflict of interest: P. Bordier has nothing to disclose. Conflict of interest: A. Lataste has nothing to disclose. Conflict of interest: S. Orazio has nothing to disclose. Conflict of interest: J. Papin has nothing to disclose. Conflict of interest: F. Robert has nothing to disclose. Conflict of interest: G. Bourenane has nothing to disclose., (Copyright ©ERS 2021.)
- Published
- 2021
- Full Text
- View/download PDF
33. Antimicrobial Resistance of Escherichia coli and Pseudomonas aeruginosa from Companion Birds.
- Author
-
Varriale L, Dipineto L, Russo TP, Borrelli L, Romano V, D'Orazio S, Pace A, Menna LF, Fioretti A, and Santaniello A
- Abstract
Antimicrobial resistance is a public health concern worldwide and it is largely attributed to the horizontal exchange of transferable genetic elements such as plasmids carrying integrons. Several studies have been conducted on livestock showing a correlation between the systemic use of antibiotics and the onset of resistant bacterial strains. In contrast, although companion birds are historically considered as an important reservoir for human health threats, little information on the antimicrobial resistance in these species is available in the literature. Therefore, this study was aimed at evaluating the antimicrobial resistance of Escherichia coli and Pseudomonas aeruginosa isolated from 755 companion birds. Cloacal samples were processed for E. coli and P. aeruginosa isolation and then all isolates were submitted to antimicrobial susceptibility testing. P. aeruginosa was isolated in 59/755 (7.8%) samples, whereas E. coli was isolated in 231/755 (30.7%) samples. Most strains showed multidrug resistance. This study highlights that companion birds may act as substantial reservoirs carrying antimicrobial resistance genes which could transfer directly or indirectly to humans and animals, and from a One Health perspective this risk should not be underestimated.
- Published
- 2020
- Full Text
- View/download PDF
34. [The patient in clinical research: disposable guinea pig or involved actor?]
- Author
-
Cosmi F, Mariottoni B, Tarquini B, D'Orazio S, Bennati M, Morganti M, and Cosmi D
- Subjects
- Adult, Decision Making, Female, Humans, Male, Middle Aged, Motivation, Patient Selection, Research Subjects, Surveys and Questionnaires, Trust, Clinical Trials as Topic, Informed Consent, Patient Participation psychology
- Abstract
Background: The request for informed consent to join a clinical trial often creates mistrust and hesitation in the patient who should be enrolled. In our study, we evaluated the reasons for refusing to participate in a clinical trial., Methods: In the last 10 years of cardiovascular clinical research, we asked an informed consent to 2586 patients for intervention studies. Overall, 59% agreed to join clinical trials, 40% refused. The 1% initially accepted and then withdrew the consent. Those who refused were more frequently women, relatively younger (mean age 62 ± 5 vs 74 ± 9 years) and had a higher level of education and income. We asked all these patients who refused to answer a brief questionnaire about the reasons for rejection., Results: Of 1031 patients, 629 (61%), accepted to answer the interview; 176 (28%) answered they refused on relatives', friends' or other doctors' advices, or after Internet searches; 157 (25%) answered they did not agree about how the trials were carried out (double-blind control procedure, use of placebo); 126 (20%) did not trust official medicine; 63 (10%) could not guarantee their presence at the follow-up visits; 69 (11%) did not want to undergo additional medical examinations; 31 (5%) had previous bad research experiences (feeling like a guinea pig); 7 (about 1%) refused for other reasons., Conclusions: Recruitment into clinical research studies is still a major challenge. Patients, due to a prevailing humanistic culture, are not fully aware of the importance of participation in clinical research, which is sometimes considered as exclusive economic or prestige interest. In our experience, people who refused participation in the trials were younger, with a high level of education and income, more frequently women. The researcher's task is to motivate the patient by emphasizing that participating in a study means being the actors of a treatment choice and that one is a guinea pig when taking untested therapies.
- Published
- 2020
- Full Text
- View/download PDF
35. Maternal cumulative exposure to extremely low frequency electromagnetic fields, prematurity and small for gestational age: a pooled analysis of two birth cohorts.
- Author
-
Migault L, Garlantézec R, Piel C, Marchand-Martin L, Orazio S, Cheminat M, Zaros C, Carles C, Cardis E, Ancel PY, Charles MA, de Seze R, Baldi I, and Bouvier G
- Subjects
- Adult, Female, France, Humans, Infant, Low Birth Weight, Infant, Newborn, Infant, Small for Gestational Age, Logistic Models, Odds Ratio, Pregnancy, Young Adult, Electromagnetic Fields adverse effects, Maternal Exposure adverse effects, Occupational Exposure adverse effects, Premature Birth epidemiology
- Abstract
Background: Data on the effects of extremely low frequency electromagnetic fields (ELF-EMF) on pregnancy outcomes are inconclusive., Objective: To study the relation between maternal cumulative exposure to ELF-EMF during pregnancy and the risk of prematurity or small for gestational age (SGA) in a pooled analysis of two French birth cohorts., Methods: Elfe and Epipage2 are both population-based birth cohorts initiated in 2011 and included 18 329 and 8400 births, respectively. Health data and household, mother and child characteristics were obtained from medical records and questionnaires at maternity and during follow-up. A job exposure matrix was used to assess cumulative exposure to ELF-EMF during three periods: (1) until 15 weeks of gestation, (2) until 28 weeks of gestation and (3) until 32 weeks of gestation. Analyses were restricted to single live births in mainland France and to mothers with documented jobs (N=19 894). Adjusted logistic regression models were used., Results: According to the period studied, 3.2%-4% of mothers were classified as highly exposed. Results were heterogeneous. Increased risks of prematurity were found among low exposed mothers for the three periods, and no association was observed among the most exposed (OR
1 =0.92 (95% CI 0.74 to 1.15); OR2 =0.98 (95% CI 0.80 to 1.21); OR3 =1.14 (95% CI 0.92 to 1.41)). For SGA, no association was observed with the exception of increased risk among the low exposed mothers in period 2 and the most exposed in period 3 (OR=1.25 (95% CI 1.02 to 1.53))., Conclusion: Some heterogeneous associations between ELF-EMF exposure and prematurity and SGA were observed. However, due to heterogeneity (ie, their independence regarding the level of exposure), associations cannot be definitely explained by ELF-EMF exposure., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2020
- Full Text
- View/download PDF
36. Gastric MALT lymphoma in a population-based study in France: clinical features, treatments and survival.
- Author
-
Matysiak-Budnik T, Jamet P, Ruskoné-Fourmestraux A, de Mascarel A, Velten M, Maynadié M, Woronoff AS, Trétarre B, Marrer E, Delafosse P, Ligier K, Lapôtre Ledoux B, Daubisse L, Bouzid L, Orazio S, Cowppli-Bony A, and Monnereau A
- Subjects
- Adult, Aged, Aged, 80 and over, Female, France epidemiology, Helicobacter Infections diagnosis, Helicobacter Infections epidemiology, Helicobacter Infections pathology, Helicobacter Infections therapy, Helicobacter pylori, Humans, Male, Middle Aged, Remission Induction, Survival Analysis, Young Adult, Gastric Mucosa pathology, Lymphoma, B-Cell, Marginal Zone diagnosis, Lymphoma, B-Cell, Marginal Zone epidemiology, Lymphoma, B-Cell, Marginal Zone pathology, Lymphoma, B-Cell, Marginal Zone therapy
- Abstract
Background: Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a rare disease, and most available data on gastric MALT lymphoma (GML) come from clinical studies of selected patients treated in centres of excellence., Aims: To analyse the clinical features, management and survival of GML patients in a population-based study in France METHODS: All new cases of GML diagnosed between 2002 and 2010 in 11 French areas covered by cancer registries were included. Pathology reports were verified and, if necessary, reviewed by an expert pathologist. All clinical data were retrospectively collected from medical files and analysed using stata V. 14 software., Results: Four hundred and sixteen patients with confirmed GML (50% male, median age 67 years) were identified. Among them, 44 showed an early transformation into diffuse large B cell lymphoma and were considered to have had an initially missed high-grade lymphoma. At diagnosis, 76% of patients were at stage IE/II, and 24% at stage III/IV of the disease. Helicobacter pylori infection was found in 57% of the patients. Eradication treatment was administered to 76% of patients and complete remission (CR) was obtained in 39%. One hundred and ninety patients received at least one other treatment, including 10 already in CR after eradication. Altogether, CR was obtained in 70% of patients and the 5-year overall survival was 79% (95% CI [75-83])., Conclusions: In comparison to clinical series, in the general population, GMLs are more frequently diagnosed at an advanced stage, their clinical management is heterogeneous, and there is a risk of misdiagnosis and overtreatment. These results highlight the necessity of following currently available guidelines in this field., (© 2019 John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
37. Novel analytical methods to interpret large sequencing data from small sample sizes.
- Author
-
Lichou F, Orazio S, Dulucq S, Etienne G, Longy M, Hubert C, Groppi A, Monnereau A, Mahon FX, and Turcq B
- Subjects
- Adult, Aged, Aged, 80 and over, Alleles, Drug Resistance, Neoplasm genetics, Female, Humans, Imatinib Mesylate administration & dosage, Imatinib Mesylate adverse effects, Leukemia, Myelogenous, Chronic, BCR-ABL Positive genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology, Male, Middle Aged, Mutation genetics, Pharmacogenomic Variants genetics, Prognosis, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Sample Size, UDP-Glucuronosyltransferase 1A9, Young Adult, DNA-Binding Proteins genetics, Endonucleases genetics, Glucuronosyltransferase genetics, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Nuclear Proteins genetics, Protein Tyrosine Phosphatase, Non-Receptor Type 22 genetics, Transcription Factors genetics
- Abstract
Background: Targeted therapies have greatly improved cancer patient prognosis. For instance, chronic myeloid leukemia is now well treated with imatinib, a tyrosine kinase inhibitor. Around 80% of the patients reach complete remission. However, despite its great efficiency, some patients are resistant to the drug. This heterogeneity in the response might be associated with pharmacokinetic parameters, varying between individuals because of genetic variants. To assess this issue, next-generation sequencing of large panels of genes can be performed from patient samples. However, the common problem in pharmacogenetic studies is the availability of samples, often limited. In the end, large sequencing data are obtained from small sample sizes; therefore, classical statistical analyses cannot be applied to identify interesting targets. To overcome this concern, here, we described original and underused statistical methods to analyze large sequencing data from a restricted number of samples., Results: To evaluate the relevance of our method, 48 genes involved in pharmacokinetics were sequenced by next-generation sequencing from 24 chronic myeloid leukemia patients, either sensitive or resistant to imatinib treatment. Using a graphical representation, from 708 identified polymorphisms, a reduced list of 115 candidates was obtained. Then, by analyzing each gene and the distribution of variant alleles, several candidates were highlighted such as UGT1A9, PTPN22, and ERCC5. These genes were already associated with the transport, the metabolism, and even the sensitivity to imatinib in previous studies., Conclusions: These relevant tests are great alternatives to inferential statistics not applicable to next-generation sequencing experiments performed on small sample sizes. These approaches permit to reduce the number of targets and find good candidates for further treatment sensitivity studies.
- Published
- 2019
- Full Text
- View/download PDF
38. mSphere of Influence: the View from the Microbiologists of the Future.
- Author
-
Mitchell A, Blader I, Bradford P, D'Orazio S, Duprex WP, Ellermeier CD, Fernandez-Sesma A, Imperiale MJ, McMahon K, Pasetti MF, and Tringe S
- Subjects
- Humans, Laboratory Personnel psychology, Microbiology education, Laboratory Personnel education, Microbiology trends
- Published
- 2019
- Full Text
- View/download PDF
39. Completion of an Experiment.
- Author
-
Imperiale MJ, Blader I, Bradford P, D'Orazio S, Duprex WP, Ellermeier CD, Fernandez-Sesma A, McMahon K, Mitchell A, Pasetti MF, and Tringe S
- Published
- 2018
- Full Text
- View/download PDF
40. [The use of mechanical chest compression devices for both out-of-hospital and in-hospital refractory cardiac arrest].
- Author
-
Russo A, Gasparetto N, Favero L, Caico SI, Orazio S, Garzena G, Rosi P, and Olivari Z
- Subjects
- Equipment Design, Hospitalization, Humans, Out-of-Hospital Cardiac Arrest therapy, Cardiopulmonary Resuscitation instrumentation, Heart Arrest therapy
- Abstract
The purpose of cardiopulmonary resuscitation after sudden cardiac arrest is to restore minimal blood flow to provide oxygen to the brain and other vital organs. Chest compressions and external defibrillation are the first line for circulatory support. Although early defibrillation is the main factor influencing survival, cardiopulmonary resuscitation must be characterized by high-quality external chest compressions. Unfortunately, the performance of manual chest compressions decreases during time and in hostile conditions. For these reasons, mechanical devices for chest compression are able to support rescuers during cardiopulmonary resuscitation. Commonly used mechanical chest compression devices in Europe include LUCAS and Autopulse. Routine utilization of mechanical chest compression devices cannot be recommended because randomized controlled trials, such as LINC and PARAMEDIC for LUCAS and CIRC for Autopulse, have not demonstrated their superiority compared with manual chest compressions. The aim of this review is to analyze recent data regarding utilization of mechanical chest compression devices, and to clarify advantages and limitations.
- Published
- 2017
- Full Text
- View/download PDF
41. Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role?
- Author
-
Le Guyader-Peyrou S, Orazio S, Dejardin O, Maynadié M, Troussard X, and Monnereau A
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Comorbidity, Factor Analysis, Statistical, Female, France epidemiology, Humans, Lymphoma, Large B-Cell, Diffuse epidemiology, Male, Middle Aged, Patient Outcome Assessment, Prognosis, Registries, Social Class, Survival Analysis, Young Adult, Lymphoma, Large B-Cell, Diffuse mortality, Population Surveillance
- Abstract
The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were performed and missing data were controlled with the multiple imputation method. In a multivariate analysis, adjusted for age, sex and International Prognostic Index, we confirmed that time period was associated with a better 5-year relative survival. The registry area, the medical specialty of the care department (onco-hematology versus other), the time to travel to the nearest teaching hospital, the place of treatment (teaching versus not-teaching hospital -borderline significance), a comorbidity burden and marital status were independently associated with the 5-year relative survival. Adjusted for first-course treatment, inclusion in a clinical trial and treatment discussion in a multidisciplinary meeting were strongly associated with a better survival outcome. In contrast, socio-economic status (determined using the European Deprivation Index) was not associated with outcome. Despite therapeutic advances, various non-biological factors affected the relative survival of patients with diffuse large B-cell lymphoma. The notion of lymphoma-specific expertise seems to be essential to achieve optimal care management and reopens the debate regarding centralization of these patients' care in hematology/oncology departments., (Copyright© Ferrata Storti Foundation.)
- Published
- 2017
- Full Text
- View/download PDF
42. Campylobacter coli infection in pet birds in southern Italy.
- Author
-
Dipineto L, Borrelli L, Pace A, Romano V, D'Orazio S, Varriale L, Russo TP, and Fioretti A
- Subjects
- Animals, Birds, Campylobacter coli genetics, Campylobacter coli isolation & purification, Disease Reservoirs, Italy epidemiology, Polymerase Chain Reaction, Prevalence, Bird Diseases epidemiology, Bird Diseases microbiology, Campylobacter Infections epidemiology, Campylobacter Infections microbiology, Feces microbiology, Pets
- Abstract
Avian species are considered as the main reservoir of Campylobacter spp. However, few data are available on the presence of this microorganism in pet birds. This study was therefore performed to determine the prevalence of Campylobacter spp. in pet birds bred in southern Italy. Faecal samples were collected from 88 cages housing different species of pet birds and examined by bacteriological culture and polymerase chain reaction. A total of 13.6% of the cage samples were positive for Campylobacter coli. Other Campylobacter spp. were not found. The study shows that C. coli can be isolated from the cages of apparently healthy pet birds, which should therefore be considered as potential carriers of C. coli and a possible source of infection for humans and companion animals.
- Published
- 2017
- Full Text
- View/download PDF
43. Assessment of Right Ventricular Function in Obstructive Sleep Apnea Syndrome and Effects of Continuous Positive Airway Pressure Therapy: A Pilot Study.
- Author
-
Vitarelli A, Terzano C, Saponara M, Gaudio C, Mangieri E, Capotosto L, Pergolini M, D'Orazio S, Continanza G, and Cimino E
- Subjects
- Echocardiography, Three-Dimensional, Female, Follow-Up Studies, Heart Ventricles physiopathology, Humans, Male, Middle Aged, Pilot Projects, Polysomnography, ROC Curve, Reproducibility of Results, Severity of Illness Index, Sleep Apnea, Obstructive diagnosis, Sleep Apnea, Obstructive physiopathology, Stroke Volume physiology, Systole, Continuous Positive Airway Pressure methods, Heart Ventricles diagnostic imaging, Sleep Apnea, Obstructive therapy, Ventricular Function, Right physiology
- Abstract
Background: It is known that obstructive sleep apnea syndrome (OSAS) can affect right ventricular (RV) performance even in the absence of systemic hypertension and other known cardiac or obstructive pulmonary disease. The purpose of the present study was to assess RV function in OSAS using 3-D echocardiography and speckle tracking echocardiography (STE) and evaluate changes after continuous positive airway pressure (CPAP) treatment., Methods: Thirty-seven patients with OSAS without comorbidities and thirty control subjects were studied using 3-D echocardiography and STE. Fifteen patients underwent CPAP therapy and were studied before and after treatment. RV 3-D ejection fraction was calculated. Peak systolic strain was determined. RV dyssynchrony was defined as SD of the 6 time to peak systolic strain values., Results: 3-D RV ejection fraction was lower and RV dyssynchrony was greater in patients with moderate-severe OSAS compared with control subjects in the presence and absence of pulmonary hypertension. 3-D RV ejection fraction and RV dyssynchrony were independently associated with apnea-hypopnea index. Patients treated with CPAP had significant changes in RV parameters., Conclusions: 3-D RV ejection fraction and RV dyssynchrony were abnormal in OSAS patients compared with control subjects and associated with OSAS severity. RV 3-D STE abnormalities improved after chronic application of CPAP., (Copyright © 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
44. Three-dimensional echocardiography and 2D-3D speckle-tracking imaging in chronic pulmonary hypertension: diagnostic accuracy in detecting hemodynamic signs of right ventricular (RV) failure.
- Author
-
Vitarelli A, Mangieri E, Terzano C, Gaudio C, Salsano F, Rosato E, Capotosto L, D'Orazio S, Azzano A, Truscelli G, Cocco N, and Ashurov R
- Subjects
- Adult, Aged, Area Under Curve, Cardiac Catheterization, Case-Control Studies, Chronic Disease, Female, Heart Failure etiology, Heart Failure mortality, Heart Failure physiopathology, Humans, Hypertension, Pulmonary complications, Hypertension, Pulmonary mortality, Hypertension, Pulmonary physiopathology, Image Interpretation, Computer-Assisted, Male, Middle Aged, Predictive Value of Tests, Prognosis, ROC Curve, Risk Factors, Ventricular Dysfunction, Right etiology, Ventricular Dysfunction, Right mortality, Ventricular Dysfunction, Right physiopathology, Echocardiography, Doppler, Echocardiography, Three-Dimensional, Heart Failure diagnostic imaging, Hemodynamics, Hypertension, Pulmonary diagnostic imaging, Ventricular Dysfunction, Right diagnostic imaging, Ventricular Function, Right
- Abstract
Background: Our aim was to compare three-dimensional (3D) and 2D and 3D speckle-tracking (2D-STE, 3D-STE) echocardiographic parameters with conventional right ventricular (RV) indexes in patients with chronic pulmonary hypertension (PH), and investigate whether these techniques could result in better correlation with hemodynamic variables indicative of heart failure., Methods and Results: Seventy-three adult patients (mean age, 53±13 years; 44% male) with chronic PH of different etiologies were studied by echocardiography and cardiac catheterization (25 precapillary PH from pulmonary arterial hypertension, 23 obstructive pulmonary heart disease, and 23 postcapillary PH from mitral regurgitation). Thirty healthy subjects (mean age, 54±15 years; 43% male) served as controls. Standard 2D measurements (RV-fractional area change-tricuspid annular plane systolic excursion) and mitral and tricuspid tissue Doppler annular velocities were obtained. RV 3D volumes and global and regional ejection fraction (3D-RVEF) were determined. RV strains were calculated by 2D-STE and 3D-STE. RV 3D global-free-wall longitudinal strain (3DGFW-RVLS), 2D global-free-wall longitudinal strain (GFW-RVLS), apical-free-wall longitudinal strain, basal-free-wall longitudinal strain, and 3D-RVEF were lower in patients with precapillary PH (P<0.0001) and postcapillary PH (P<0.01) compared to controls. 3DGFW-RVLS (hazard ratio 4.6, 95% CI 2.79 to 8.38, P=0.004) and 3D-RVEF (hazard ratio 5.3, 95% CI 2.85 to 9.89, P=0.002) were independent predictors of mortality. Receiver operating characteristic curves showed that the thresholds offering an adequate compromise between sensitivity and specificity for detecting hemodynamic signs of RV failure were 39% for 3D-RVEF (AUC 0.89), -17% for 3DGFW-RVLS (AUC 0.88), -18% for GFW-RVLS (AUC 0.88), -16% for apical-free-wall longitudinal strain (AUC 0.85), 16 mm for tricuspid annular plane systolic excursion (AUC 0.67), and 38% for RV-FAC (AUC 0.62)., Conclusions: In chronic PH, 3D, 2D-STE and 3D-STE parameters indicate global and regional RV dysfunction that is associated with RV failure hemodynamics better than conventional echo indices., (© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.)
- Published
- 2015
- Full Text
- View/download PDF
45. Short- and long-term effects of nocturnal oxygen therapy on sleep apnea in chronic heart failure.
- Author
-
Bordier P, Orazio S, Hofmann P, Robert F, and Bourenane G
- Subjects
- Aged, Chronic Disease, Female, Follow-Up Studies, Heart Failure diagnosis, Heart Failure physiopathology, Humans, Male, Middle Aged, Polysomnography, Quality of Life, Sleep Apnea, Obstructive diagnosis, Sleep Apnea, Obstructive physiopathology, Ventricular Function, Left physiology, Heart Failure therapy, Oxygen Inhalation Therapy methods, Sleep Apnea, Obstructive therapy
- Abstract
Purpose: This paper studies the short- and long-term effects of nocturnal oxygen therapy (NOT) on sleep apnea in chronic heart failure (CHF)., Methods: We enrolled 51 adults in New York Heart Association (NYHA) heart failure functional classes II or III, ≤45 % left ventricular ejection fraction (LVEF), in a randomized, open, single-center study. Nocturnal cardiorespiratory polygraphy showed sleep apnea [apnea-hypopnea index (AHI) ≥15 events/h] in 33 patients, of whom 19 were randomly assigned to NOT, 3.0 l/min, and 14 to no NOT. The NOT group underwent follow-up polygraphy at 24 h and 6 months, and the no NOT group a single follow-up polygraphy at 6 months., Results: No significant difference was observed between baseline and 6 months in the no NOT group. In the NOT group, AHI decreased from 36.8 ± 2.6 events/h at baseline to 20.8 ± 3.0 at 24 h and to 18.3 ± 2.4 at 6 months (both P < 0.0001 vs. baseline), due to central AHI changes from 23.3 ± 2.8 events/h at baseline to 8.3 ± 1.6 at 24 h and to 6.1 ± 1.4 at 6 months (both P < 0.0001 vs. baseline). Oxygen desaturation index (ODI) decreased from 33.0 ± 5.2 events/h at baseline to 7.5 ± 0.5 at 24 h and 9.3 ± 2.6 at 6 months (both P < 0.0001 vs. baseline). NOT had no significant effect on obstructive and mixed AHI, quality of life (QOL), NYHA class, and LVEF up to 6 months of follow-up., Conclusions: NOT decreased central AHI and ODI significantly within 24 h and up to 6 months in CHF patients with sleep apnea, without significantly modifying obstructive and mixed AHI, QOL, and ventricular function.
- Published
- 2015
- Full Text
- View/download PDF
46. A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis.
- Author
-
Perani D, Schillaci O, Padovani A, Nobili FM, Iaccarino L, Della Rosa PA, Frisoni G, and Caltagirone C
- Subjects
- Glucose-6-Phosphate therapeutic use, Humans, Radiography, Alzheimer Disease diagnostic imaging, Alzheimer Disease metabolism, Amyloid metabolism, Glucose-6-Phosphate analogs & derivatives, Positron-Emission Tomography methods, Radiopharmaceuticals therapeutic use
- Abstract
PET based tools can improve the early diagnosis of Alzheimer's disease (AD) and differential diagnosis of dementia. The importance of identifying individuals at risk of developing dementia among people with subjective cognitive complaints or mild cognitive impairment has clinical, social, and therapeutic implications. Within the two major classes of AD biomarkers currently identified, that is, markers of pathology and neurodegeneration, amyloid- and FDG-PET imaging represent decisive tools for their measurement. As a consequence, the PET tools have been recognized to be of crucial value in the recent guidelines for the early diagnosis of AD and other dementia conditions. The references based recommendations, however, include large PET imaging literature based on visual methods that greatly reduces sensitivity and specificity and lacks a clear cut-off between normal and pathological findings. PET imaging can be assessed using parametric or voxel-wise analyses by comparing the subject's scan with a normative data set, significantly increasing the diagnostic accuracy. This paper is a survey of the relevant literature on FDG and amyloid-PET imaging aimed at providing the value of quantification for the early and differential diagnosis of AD. This allowed a meta-analysis and GRADE analysis revealing high values for PET imaging that might be useful in considering recommendations.
- Published
- 2014
- Full Text
- View/download PDF
47. Left ventricular torsion abnormalities in patients with obstructive sleep apnea syndrome: an early sign of subclinical dysfunction.
- Author
-
Vitarelli A, D'Orazio S, Caranci F, Capotosto L, Rucos R, Iannucci G, Continanza G, Dettori O, De Cicco V, Vitarelli M, De Maio M, De Chiara S, and Saponara M
- Subjects
- Adult, Cohort Studies, Early Diagnosis, Female, Heart Ventricles parasitology, Humans, Male, Middle Aged, Polysomnography methods, Sleep Apnea, Obstructive epidemiology, Sleep Apnea, Obstructive physiopathology, Torsion Abnormality epidemiology, Torsion Abnormality physiopathology, Ultrasonography, Ventricular Dysfunction, Left epidemiology, Ventricular Dysfunction, Left physiopathology, Heart Ventricles abnormalities, Heart Ventricles diagnostic imaging, Sleep Apnea, Obstructive diagnostic imaging, Torsion Abnormality diagnostic imaging, Ventricular Dysfunction, Left diagnostic imaging
- Abstract
Background: Previous echocardiographic studies using tissue Doppler imaging (TDI) and speckle tracking imaging (STI) have demonstrated that obstructive sleep apnea syndrome (OSAS) patients may develop subclinical left ventricular (LV) systolic and diastolic dysfunction. Our purpose was to evaluate the impact of OSAS on LV torsion dynamics and aortic stiffness by using TDI and STI echocardiography., Methods: Forty-two patients with OSAS and no comorbidities were studied. They were classified into mild and severe OSAS according to the apnea-hypopnea index (AHI). Thirty-five healthy subjects were selected as controls. Fifteen patients with severe OSAS underwent chronic nocturnal nasal continuous positive airway pressure (CPAP) therapy. Standard echocardiographic parameters were assessed. Global LV longitudinal strain (LS), radial and circumferential strain were determined by STI. Averaged LV rotation and rotational velocities from the base and apex were obtained and used for calculation of LV torsion (LVtor). Mitral annular velocities and aortic wall velocities and strain (AoS) were also obtained by TDI., Results: Severe OSAS had decreased LS compared with control subjects. LVtor increased significantly in severe OSAS compared to normals (p<.001) as a result of a predominant increase in apical rotation and was independently related to AHI and AoS in a multiple stepwise linear regression model. The group treated with CPAP had a significant decrease in LVtor and aortic stiffness index and significant increase in LS and AoS., Conclusions: LVtor, LS and AoS were identified as parameters demonstrating an association between LV dysfunction, aortic stiffness and severity of OSAS independently of other possible factors or comorbidities., (Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
48. Assessment of right ventricular function by three-dimensional echocardiography and myocardial strain imaging in adult atrial septal defect before and after percutaneous closure.
- Author
-
Vitarelli A, Sardella G, Roma AD, Capotosto L, De Curtis G, D'Orazio S, Cicconetti P, Battaglia D, Caranci F, De Maio M, Bruno P, Vitarelli M, De Chiara S, and D'Ascanio M
- Subjects
- Adolescent, Adult, Algorithms, Case-Control Studies, Echocardiography, Doppler, Color, Female, Heart Septal Defects, Atrial physiopathology, Humans, Image Interpretation, Computer-Assisted, Male, Middle Aged, Multivariate Analysis, Observer Variation, Predictive Value of Tests, Reproducibility of Results, Septal Occluder Device, Software, Stroke Volume, Time Factors, Treatment Outcome, Young Adult, Cardiac Catheterization instrumentation, Echocardiography, Three-Dimensional, Heart Septal Defects, Atrial diagnostic imaging, Heart Septal Defects, Atrial therapy, Myocardial Contraction, Ventricular Function, Right
- Abstract
Real-time three-dimensional (3D) echocardiography allows us to measure right ventricular (RV) end-diastolic volume irrespective of its shape. Tissue Doppler imaging (TDI) and speckle tracking imaging (STI) are new tools to assess myocardial function. We sought to evaluate RV function by 3D echocardiography and myocardial strain imaging in adult patients with atrial septal defect (ASD) before and 6 months after transcatheter closure in order to assess the utility of these new indexes in comparison with standard two-dimensional (2D) and Doppler parameters. Thirty-nine ASD patients and 39 healthy age- and sex-matched controls were studied using a commercially available cardiovascular ultrasound system. 2D-Doppler parameters of RV function (fractional area change, tricuspid annular plane systolic excursion, myocardial performance index) were calculated. 3D RV volumes were also obtained. RV peak-systolic velocities, peak-systolic strain, and peak systolic and diastolic strain-rate were measured in the basal, mid and apical segments of lateral and septal walls in apical 4-chamber view by TDI and STI. In open ASD, RV ejection fraction (3D-RVEF) and global and regional RV longitudinal strain were significantly higher than control group and decreased significantly after closure. By multivariate analysis 3D-RVEF, apical strain and strain rate were independent predictors of functional class. ROC analysis showed 3D-RVEF and apical strain to be more sensitive predictors of unfavorable outcome after defect closure compared to 2D-Doppler indexes. 3D echocardiography and myocardial strain imaging give useful insights in the quantitative assessment of RV function in ASD patients before and after closure.
- Published
- 2012
- Full Text
- View/download PDF
49. Assessment of ascending aorta distensibility after successful coarctation repair by strain Doppler echocardiography.
- Author
-
Vitarelli A, Conde Y, Cimino E, D'Orazio S, Stellato S, Battaglia D, Padella V, Caranci F, Continanza G, Dettori O, and Capotosto L
- Subjects
- Adolescent, Adult, Aortic Coarctation physiopathology, Blood Pressure, Case-Control Studies, Elasticity, Female, Heart Ventricles diagnostic imaging, Heart Ventricles physiopathology, Humans, Hypertension etiology, Male, Middle Aged, Systole, Ventricular Dysfunction, Left diagnostic imaging, Ventricular Dysfunction, Left physiopathology, Aorta diagnostic imaging, Aorta physiopathology, Aortic Coarctation surgery, Echocardiography, Doppler
- Abstract
Background: Increased arterial stiffness may participate in the genesis of hypertension and increase of left ventricular (LV) mass after surgical correction of coarctation of the aorta. The purpose of the current study was to assess the aortic elastic properties using Doppler tissue imaging and strain rate imaging in patients after coarctoplasty., Methods: Echocardiography with Doppler tissue/strain rate imaging capabilities was performed in 26 adult normotensive patients who had successful repair of coarctation of the aorta in infancy and in 24 control subjects. Transesophageal aortic transverse sections were imaged at the level of the proximal and distal segments to the repair site. Doppler tissue imaging wall velocities during systole (S(w)), early relaxation (E(w)), and atrial systole (A(w)) and peak systolic strain (ps epsilon) were measured in both groups. Transthoracic ascending aorta (AAo) measurements were also obtained., Results: In the patients with coarctoplasty, S(w) velocities and ps epsilon were significantly decreased in the proximal segments compared with control subjects. Both peak systolic blood pressure after exercise (P < .001) and pulse pressure after exercise (P < .001) were directly related to AAo wall strain. LV annular early diastolic velocity was significantly reduced compared with control subjects in patients with decreased AAo wall strain and exercise-induced hypertension (P < .001) and related to AAo wall velocity (P < .005) and strain (P < .001). In multiple linear regression analysis, only weight, study group, and AAo wall strain were correlated to LV mass index., Conclusions: Patients with coarctation of the aorta have reduced proximal aortic wall velocities and strain and increased stiffness even after successful repair. This amplifies stress-induced hypertension and increases LV burden.
- Published
- 2008
- Full Text
- View/download PDF
50. Assessment of severity in aortic stenosis-incremental value of endocardial function parameters compared with standard indexes.
- Author
-
Vitarelli A, Morichetti MC, Conde Y, Cimino E, D'Orazio S, Stellato S, Padella V, Caranci F, and Battaglia D
- Subjects
- Adolescent, Adult, Aortic Valve Stenosis pathology, Aortic Valve Stenosis physiopathology, Aortic Valve Stenosis surgery, Blood Flow Velocity, Echocardiography, Doppler methods, Endocardium diagnostic imaging, Female, Humans, Image Processing, Computer-Assisted methods, Male, Middle Aged, Observer Variation, Postoperative Period, Prospective Studies, Severity of Illness Index, Stroke Volume, Ventricular Function, Left, Aortic Valve Stenosis diagnostic imaging
- Abstract
Several studies have reported that patients (pts) with severe aortic stenosis and similar pressure gradients or even similar aortic valve areas may have quite different symptomatic status and clinical outcomes suggesting that other factors might have a significant impact on the pathophysiology of this disease. Our purpose was to assess the severity of subendocardial wall dysfunction in symptomatic and asymptomatic pts with aortic stenosis using tissue Doppler imaging (TDI), strain rate imaging (SRI) and cyclic variation of integrated backscatter (IB). We studied 68 pts with aortic valvar stenosis and 46 subjects with no signs of heart disease. SRI/IB indexes were calculated in the apical four chambers views at endocardial level. Early diastolic endocardial strain rate showed the best correlation with transvalvar pressure gradients and valve areas. Compared with controls, symptomatic pts showed a more marked decrease in endocardial strain, strain rate and cyclic variation of IB. Receiver operating characteristic (ROC) curves suggested that the thresholds offering an adequate compromise between sensitivity and specificity for the prediction of symptoms were >/=60 mm Hg for the pressure gradient, less than 0.60 cm(2)/m(2) for aortic valve area, less than 20% for strain, less than 2.0 s(-1) for strain rate and less than 3.0 dB for cyclic variation. The combination of pressure gradient, aortic valve area and SRI/IB parameters resulted in an improvement of the overall performance for predicting the symptomatic state. Thus, SRI/IB parameters have an incremental value in differentiating symptomatic and asymptomatic pts with aortic stenosis compared with conventional hemodynamic parameters.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.